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INTRODUCTION
1 INTRODUCTION
1.1 The structure of double-stranded DNA
In  the  year  1953,  James  Watson and Francis  Crick  revolutionized the  field  of  natural 
sciences by proposing the tree-dimensional structure of DNA, the molecule of life (Watson 
& Crick, 1953). DNA (deoxyribonucleic acid) holds the complete genetic information of 
the cell, determining its existence, structural basis and function. The first crystallographic 
structure solved in 1982, confirmed the proposed model by the two Nobel Prize winners 
(Dickerson  et  al., 1982;  Drew  et  al., 1982).  The two single-stranded DNA molecules, 
wrapped around antiparallel to each other, form the double-stranded nucleic acid polymer, 
where  the  nucleobases  are  connected  by  the  sugar  phosphate  backbone.  Each  
2’-deoxyribose residue is bound to one of the four nucleobases adenine (A), cytosine (C), 
guanine  (G)  or  thymine (T) by  a  β-glycosidic  bond.  The form of  the  double  helix  is 
determined by base pairing between A and T, or C and G, where two, respectively three 
Watson-Crick bonds can be formed (Figure 1). All base pairs (bp) in the double helix are 
positioned above each other in a stacking arrangement. On the surface of the double helical 
structure, one can distinguish the minor and the major groove. 
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Figure 1: Watson-Crick base pairing.
The genome carries information in two forms. The genetic information is stored in the 
nucleotide sequence and is a blueprint for protein production needed for existence, while 
the epigenetic information gives the instructions,  on when and where the genetic  code 
should be read. The major form of epigenetic information is the methylation of cytosine or 
adenine, a process catalyzed by DNA methyltransferases. 
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1.2 DNA methylation
1.2.1 DNA methyltransferases
Biological DNA methylation is a natural process that inserts additional information on the 
epigenetic level (after the replication process) and differs from chemical methylation as in 
damaged  DNA.  DNA  methylation  is  an  enzymatic  reaction  catalyzed  by  DNA 
methyltransferases  (MTases),  which  transfer  the  activated  methyl  group  from  the 
ubiquitous  cofactor  S-adenosyl-L-methionine  (AdoMet,  1)  to  the  target  base  in  a 
determined nucleotide sequence, which can expand from two to eight base pairs lengh. 
After the transfer process, the demethylated cofactor AdoHcy (2) is set free and functions 
as a competitive inhibitor for most MTases (Scheme 1). The methyl group is positioned in 
the DNA major groove and can be easily detected by proteins interacting with DNA.
The first methylated DNA base, C5-methylcytosine, was discovered in calf thymus DNA 
by Rollin  Hotchkiss  in  1948 (Hotchkiss,  1948).  N6-methyladenine was found by John 
Smith in 1955 (Dunn & Smith, 1955), whereas the third modified base, N4-methylcytosine, 
was not known until 1983 (Figure 2). The MTases forming these bases are divided into two 
families.  The ones that form 5-methylcytosine (m5C) have several  conserved sequence 
motifs in prokaryotic MTases and in the CpG MTases found in higher eukaryotes. The 
second family responsible for forming  N6-methyladenine (m6A) and  N4-methylcytosine 
(m4C) also shows several characteristic sequence motifs, but they cannot be differentiated 
from each other on the level of protein sequence similarity.
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Figure 2: Structures of methylated nucleobases naturally occurring in DNA.
The methylation pattern can be erased during the process of DNA replication. Because the 
target sequences for  MTases are usually palindromic,  the methylation mark is  on both 
DNA strands. During semiconservative replication, these sites become hemimethylated and 
can be converted into the fully methylated state (Jeltsch, 2002).
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Scheme 1: Methyl group transfer to target nucleobases in different DNA recognition sequences, by 
DNA cytosine-C5, DNA cytosine-N4 or DNA adenine-N6 MTase, respectively.
The target nucleobases for methylation by DNA MTases are buried deep in the double 
helix  structure.  Therefore, nature  has  developed  a  specific  feature  of  the  catalytic 
mechanism called “base  flipping”,  where  the  bound enzyme reveals  the  nucleotide  by 
placing it  in its  active site next to the cofactor AdoMet (1).  This mechanism has been 
studied and proven for several DNA MTases, M.HhaI (Klimasauskas et al., 1994), M.TaqI 
(Goedecke et al., 2001) or M.HaeIII (Reinisch et al., 1995) by co-crystallizing the enzyme 
with short duplex oligonucleotides (duplex ODN) containing the target sequences (Figure
3).  DNA MTases form a  ternary  complex  with  DNA and  AdoMet  (1).  With different 
enzymes,  the  substrates  are  known  to  bind  to  the  enzyme  sequentially  or  randomly 
(Lindstrom et al., 2000; Reich & Mashhoon, 1991). Specific binding of DNA is associated 
with major conformational changes of the formed complex. It has been well studied for 
enzymes,  which  structures  in  the  DNA-free  and  DNA-bound  form  have  been  solved 
(Cheng  et  al.,  1993;  Klimasauskas et  al.,  1994;  Labahn  et  al.,  1994;  Goedecke  et  al., 
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2001). Yet, before the DNA-binding enzyme finds its target sequence, it interacts with the 
double  helix,  initially  in  a  nonspecific  way  and  then scans  for  its  sequence  by  linear 
diffusion (Surby & Reich, 1996; Gowher et al., 2000).
M.HhaI M.HaeIII M.TaqI
Figure 3: Crystal structures of DNA MTases bound to their substrate DNA. From the left: M.HhaI 
(pdb ID 5mht), M.HaeIII (pdb ID 1dct)  and M.TaqI (pdb ID 1g38).  The flipped out  base is 
indicated in red, DNA in green, protein ribbon in blue. In the case of M.HhaI and M.TaqI the 
cofactor is indicated in yellow. Data taken from the PDB (protein data bank). 
The best-characterized enzyme from the  N-DNA MTases class is M.TaqI from  Thermus 
aquaticus.  Labahn determined the  first  crystal  structure  in  1994 and seven years  later 
Goedecke  confirmed  its  base  flipping  mechanism  by  co-crystallization  with  a  duplex 
oligonucleotide and a cofactor analog.
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On this work, also the postulated mechanism of the activation of the extrahelical N6 group 
is based. The increased electron density caused by the hydrogen bonding of the 6-amino 
group with the Asn 105 and the backbone oxygen of Pro 106 contributes in the N6 group 
activation for the nucleophilic attack (Scheme 2, Goedecke et al., 2001).
The mechanism of C5-DNA MTases is well known since the late 1980’s, when the kinetic 
and catalytic properties of M.HhaI were published (Wu & Santi  et al., 1987). Basing on 
precedents of other  enzymes,  which catalyze similar reactions it was proposed that the 
sulfhydryl group of a cysteine residue acts as a nucleophilic catalyst. It is found in a Pro-
Cys sequence motif, conserved in all cytosine-C5 DNA MTases, which sequences have 
been determined. The mechanism shown in Scheme 3 is based on the crystal structure of 
M.HhaI (Klimasauskas  et al., 1994) and M.HaeIII (Reinisch  et al.,  1995). The primary 
consideration is that C5 of cytosine is not sufficiently nucleophilic to react with a carbon 
donor as AdoMet (1). The nucleophilic thiol group of the enzyme’s cysteine moiety adds to 
C6 of  cytosine and a  proton from the  glutamate rest  in  the  active  site  neutralizes the 
negative charge. The anionic character of the C5 atom is now sufficient to allow a reaction 
with  AdoMet  (1).  A  subsequent  β-elimination  generates  C5-methylcytosine  and 
catalytically competent protein.
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Experimentally, the base flipping mechanism can be studied by integrating fluorescent base 
analogs,  such  as  2-aminopurine  in  the  target  position,  where  high  fluorescence 
enhancement is registered when the base is flipped out of the double-stranded DNA (Allan 
& Reich, 1996; Holz et al., 1998).
It has been demonstrated that nucleic acid-related compounds such as 5-azacytosine (3, 
AzaC; Johnes & Taylor, 1980), 5-fluoro cytosine (4, FdC; Osterman et al., 1988; Chen et  
al., 1991), zebularine (5, Zeb; Zhou et al., 2002) or 5,6-dihydro-5-azacytosine (6, DHAC; 
Sheikhnejad et al., 1999) act as C5-DNA MTase inhibitors, when placed in the target base 
position (Figure 4). The mode of action of 3, 4 and 5 is based on a high degree of affinity 
to the active site of the enzyme, forming a covalent complex between the sulphur atom of 
the  catalytic  cytosine  and  the  pyrimidine  C6  carbon.  Due  to  their  structures,  the  β-
elimination step, which sets the enzyme free, becomes impossible. The saturation of the 
5,6-double bond in DHAC (6) totally revokes the nucleophilic attack by the active-site 
cysteine of C5-DNA MTases. With the sp3-hybrydized C6 atom and NH at the 5th position, 
DHAC (6) mimics the non-aromatic character of the cytosine ring in the transition state 
and forms a tight non-covalent complex with enzyme. 
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Figure  4: Structures  of  C5-DNA MTases inhibitors:  5-azacytosine  (AzaC, 3),  5-fluoro-
cytosine (FdC, 4), zebularine (Zeb, 5) and 5,6-dihydro-5-azacytosine (DHAC, 6).
1.2.2  DNA methylation in prokaryotes
All of above described DNA methylation types are found in prokaryotes. They have three 
main  biological  functions.  They control  postreplicative mismatch repair  as  well  as  the 
replication cycle and protect the host DNA against endogenous restriction endonucleases 
(distinction of self and nonself DNA). 
A good example illustrating the role of DNA methylation in DNA repair and replication 
control is the Escherichia coli Dam system (DNA adenine methyltransferase). A short, few 
seconds time frame, where the methylation status changes between hemimethylation of the 
5’-GATC-3’ site (just after replication) and full  methylation (after remethylation by the 
Dam MTase), is when the mismatch repair enzymes can use the methylation mark on the 
parental  strand  and  correct  possible  errors  in  the  newly  synthesized  strand.  Dam 
methylation also serves as a replication cycle control, by labeling the parental strand after 
this process.  The other very important function of DNA methylation is defense against 
infection by bacteriophages. This issue is  associated with DNA restriction/modification 
(RM) systems, which besides the DNA MTase, consists of a DNA restriction endonuclease 
with the same recognition sequence. The cleavage takes place only on the nonself DNA 
because, in opposite to self DNA, it lacks the protective methylation mark.
1.2.3 DNA methylation in eukaryotes
In  higher  eukaryotes,  only  cytosine-C5  methylation has  been  found.  Eukaryotic  DNA 
MTases can be grouped into four distinct families based on sequence homology within the 
C-terminal  catalytic  domains.  Dnmt1,  are  enzymes  involved  in  maintaining  the 
methylation  patterns,  their  homologues  Dnmt3a/b  were  discovered  in  1998  and  are 
responsible for establishing DNA methylation (de novo  MTases). To this group belongs 
7
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also  Dnmt3L,  an  enzymatically  inactive  regulatory  factor. It  recognizes  unmethylated 
lysine 4 on histone H3 and recruits or activates the DNA de novo MTase Dnmt3a2 (Ooi et 
al., 2007). The third group is the chromomethylase family, unique for the plant kingdom 
(Goll  & Bestor, 2005).  Dnmt2 is  the  last  group, which has  been classified as a  DNA 
modifying  enzyme,  due  to  similar sequence  and  structural  characteristics  to  DNA C5 
MTases. Its residual DNA C5 MTase activity has been shown in the group of Albert Jeltsch 
(Hermann et al., 2003). Recent studies showed that Dnmt2 methylates tRNAAsp with high 
efficiency at the last nucleobase of the tRNA anticodon loop (Goll  et al., 2006). Yet the 
functional significance of the DNA/RNA specificity of the Dnmt2 family, at this point, 
remains enigmatic (Jeltsch et al., 2006). 
1.2.4 DNA methylation pattern
In mammalian DNA, 80% of all CpG sequences are thought to be in the methylated state 
(Jaenisch & Bird,  2003;  Strichman  et  al.,  2002).  CpG methylation  is  involved in cell 
differentiation  and  development  through  gene  silencing.  Methylation  levels  of  CpG 
dinucleotides  show two modes  of  distribution.  CpGs in  high CpG density regions are 
mostly unmethylated, whereas regions of low density tend to be in the methylated state 
(Meissner et al., 2008). Notably, there are some regions with enriched CpGs, termed CpG 
islands, mostly associated with gene promoter regions.  Most human  housekeeping genes 
have CpG islands at their promoters (Gardiner-Garden & Frommer, 1987; Larsen  et al., 
1992, Marino-Ramirez et al., 2004). They are over 0.2 kbp long and comprise about 1% of 
the genomic DNA (Kass et al., 1997; Ng et al., 1999). The palindromic sequence can be 
methylated on either sides by de novo (in the case of unmethylated sites) or maintenance 
methyltransferases (for hemimethylated sites e.g. after replication). DNA methylation is a 
reversible, dynamic process. It creates patterns of non- and fully methylated sites and is a 
central  mechanism in epigenetic  inheritance (inherited information,  not  encoded in the 
DNA sequence). Epigenetic mechanisms include also histone modifications (methylation, 
acetylation  and  phosphorylation),  which  influence  the  gene  regulation  and  chromatin 
accessibility by changing the form between euchromatin (light packing) to heterochromatin 
(tight packing). This process also regulates the expression of non-coding RNA molecules 
that lead to gene silencing (Matzke et al., 2001). The relation between DNA methylation, 
histone modification and non-coding RNAs is uncertain, but there is much evidence on 
their synergistic mode of action (Tamaru & Selker, 2001).
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In the broadly understood gene regulation process, the function of methylation in higher 
eukaryotes  can  be  divided  in  three  gene  repression  levels  (Kass  et  al.,  1997).   DNA 
methylation  recruits  C5-methylcytosine-binding  proteins,  which  can  repress  gene 
expression. Secondly, some transcription factors cannot bind methylated target sites. DNA 
methylation prompts histone deacetylation,  which results  in  a  chromatin change to the 
tightly packed structure and leads to gene suppression. DNA methylation is involved in 
several  processes  e.g.  gene  imprinting,  chromosome  X  inactivation  or  reduction  of 
transcriptional noise, though its contribution differs in each of these processes.
The methylation template is not only set by methylation, but also by demethylation of the 
C5-methylcytosines. Most previous studies implied that it is a passive process, caused by 
the  lack  of  maintenance  methylation,  followed  by  replication  and  cell  division. 
Nevertheless,  this  observation is  contradicted by replication independent  demethylation 
(Rougier  et  al.,  1998).  Until  now,  there  is  only  one  known  mechanism  of  active 
demethylation,  which  involves  a  DNA glycosidase  removing  the  methylated  cytosine, 
followed by lesion repair. As it is improbable, that this would be the only demethylation 
mechanism, it is suggested that also a direct C-C bond breaking system exists (Jeltsch, 
2002).
1.2.5 DNA methylation and human disease
DNA  methylation  anomalies  play  a  role  in  genetic  disease.  The  ICF  syndrome 
(immunodeficiency, centromeric  heterochromatin,  facial  anomalies)  caused  by  Dnmt3b 
mutations, is on the expanding list of genetic diseases. Rett and TR-X (mental retardation 
diseases),  both  chromosome-linked  syndromes  display  cellular  methylation  machinery 
defects (Robertson & Wolffe, 2000). Their joint symptom of mental disorder indicates that 
DNA methylation-dependent gene control pathways or chromatin structure modifications 
can be especially important for brain development. 
There are numerous examples for the direct role of methylation in carcinogenesis. Tumor 
cells  display  a  general  hypomethylation  pattern  together  with  region-specific 
hypermethylation (Ponder, 2001; Herman & Baylin, 2003; Baylin & Herman, 2000). Yet, 
no one has thoroughly understood the mutual symbiosys between cancer and methylation. 
There are four general types of cancer. Leukemias are cancers of immature blood cells, 
which grow in the bone marrow. Lymphomas emerge in the lymph nodes and tissues of the 
immune system and sacromas are cancers of the supporting tissues as bone, muscles or 
9
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connective tissue. The last and most common ones are carcinomas, which derive from cells 
that line the internal and external body surfaces, called epithelium. 
The development of malignant tumors is associated with their ability to overcome the cell-
cell adhesion and invade the surrounding tissues. Many different cell adhesion molecules 
(CAMs)  are  involved  in  human  carcinogenesis.  The  expression  of  some  adhesion 
molecules during the alternation into malignant tumor cell  is  down regulated, whereas 
others  are  induced.  A variety  of  carcinomas  strongly  overexpress  the  transmembrane 
glycoprotein  EpCAM (epithelial  cell  adhesion  molecule).  It  was  first  characterized  by 
Litvinov in 1994 (Litvinov et al., 1994), yet until now the biological function of EpCAM 
in healthy tissues and in cancer is not understood conclusively. Dynamic change of its 
expression levels is a regulated process in cancer development. For this reason, EpCAM 
has been suggested as a tumor marker and a target for immunotherapy (Armstrong & Eck, 
2003, Osta  et al., 2004). The expression of EpCAM has been associated with epigenetic 
CpG methylation changes in the promoter region. DNA MTase inhibitors, such as AzaC 
(3), have been proven to reactivate tumor suppressor genes by hypomethylation. Therefore, 
they gained a lot of attention as potential anticancer agents in the last years (overview: 
Szyf et al., 2004; Spizzo et al., 2007). Certainly, EpCAM tumor progression is regulated 
through  methylation  and  inactivation  of  EpCAM  by  selective  hypermethylation  is 
emerging as a new strategy for the prevention and treatment of cancer (Shiah et al., 2008).
1.2.6 DNA MTase from Spiroplasma sp. strain MQ1 (M.SssI)
M.SssI is a very particular prokaryotic DNA MTase, as it is the only to share its sequence 
specificity  with  the  mammalian  DNA MTases and  recognizes  the  short  dinucleotide 
sequence CpG (Nur  et al., 1985;  Scheme 4). It was successfully cloned, expressed in  E. 
coli and characterized in 1990. M.SssI is highly specific and targets exclusively CpGs with 
sequence  specificity  typical  for  mammalian  DNA MTases. Methylation  of  other  CpX 
(X=A, C, T) dinucleotide sequences has not been detected (Renbaum et al., 1990). 
10
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Scheme 4: Methyl group transfer to the target cytosine in the CpG sequence, catalyzed by M.SssI.
Similar to all prokaryotic C-DNA MTases, it is also a de novo MTase and shows equally 
high efficiency for non- and hemimethylated sequences (Renbaum & Rasin, 1992). The 
same group reported that M.SssI binds in a non-specific manner to the DNA backbone on 
both strands, screens the major groove for recognition sites and catalyzes the methylation 
reaction on one strand at a time, in a processive mechanism. These observations imply that 
the enzyme combines both specific and non-specific interactions at the recognition site. 
Since the structure of this enzyme has not yet been solved, a structural model was built of 
M.SssI in complex with the substrate DNA and its analogs as well as the cofactor product 
AdoHcy (2) using the X-ray structures of M.HhaI and M.HaeIII as templates (Koudan et 
al., 2004, Figure 5) suggesting the functionally important residues in M.SssI.
As reported by Darii, the dissociation constants (Kd) of the wild type M.SssI in a complex 
with AdoHcy (2) and DNA, displayed nM values, similar to published data for other C-
DNA MTases, like M.HhaI (Darii et al., 2007; Estabrook et al., 2004; Subach et al., 2006).
Because the CpG sequence coincides with the recognition site of eukaryotic DNA MTases, 
M.SssI is an interesting model for studying the mechanism of CpG recognition.
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Figure 5: Two views of the M.SssI model in a ternary complex with DNA and AdoHcy (2). DNA 
is indicated in green, the flipped out base in red, the protein ribbon in blue, the cofactor in yellow 
and N-, C-terminal residues together with the catalytic cysteine in magenta (van der Waals surface).
1.3 Super-specific DNA methylation
Development  of  methods  that  would  allow  inheritable  gene-specific  methylation  of 
endogenous DNA could find application in research and therapeutic studies connected to 
aberrant  methylation  pattern-derived  diseases.  There  are  few  possibilities  to  construct 
targeted DNA-binding enzymes. One can enhance their specificity on behalf of coupling to 
triple helix-forming oligonucleotides (TFOs) or synthetic polyamides. Another method is 
fusion with other DNA-binding proteins e.g. engineered transcription factors. For a number 
of proteins, including M.SssI, the alliance with zinc finger proteins has been a successful 
approach for targeted methylation in vitro and in vivo studies.
1.3.1 Triple helix DNA
The interest in DNA triplex studies started due to two rather separate observations. One 
was that homopurine-homopyrimidine stretches in plasmid DNA under supercoiled stress 
were shown to  adopt a novel  spatial,  non B-DNA structure,  called  H-DNA (Figure  6, 
Lyamichev  et  al.,  1986).  The  second  was  that  polypyrimidine  and  some  purine-rich 
oligonucleotides  can  bind  sequence-specifically  to  the  duplex  DNA (Felsenfeld  et  al., 
1957, Moser & Dervan, 1987). Since that time, the DNA triple helix became a strongly 
emerging topic because of its potential biological properties. 
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Figure 6: Model of the H form of DNA.
The  ability  of  triple  helix-forming  oligonucleotides  (TFOs)  to  bind  to  a  duplex 
oligonucleotide  has  been  used  as  a  tool  to  interact  with  several  biological  processes  
(Figure 7). In the past 20 years, it has been proven that TFOs can act as transcription 
initiation or elongation inhibitors by preventing transcription factors binding to the DNA or 
blocking the progression of the RNA polymerase complex (Cooney et al., 1988, Postel et 
al.,  1991).  They  can  deliver  various  DNA reactive  molecules  working  as  ”molecular 
scissors”  (Moser  &  Dervan,  1987;  Francois  et  al.,  1988)  or  generate  site-specific 
mutations, with the use of e.g. psoralen-linked TFOs (Kim  et al., 2006, Vasquez et al., 
2000). Where gene defects cannot be repaired by site-directed mutagenesis, TFOs can be 
applied  in  triplex-stimulated  homologous  recombination,  a  technique  to  replace  large 
fragments of DNA (Figure 7E, Faruqi et al., 2000; Chan et al., 1999). Another approach, 
which has found an application in gene therapy, is the antisense therapy, first reported in 
the early 70’s. Oligonucleotides and short interfering RNA (siRNA) molecules can form a 
double-stranded DNA with the messenger RNA (mRNA) and interrupt the normal cellular 
processing of the genetic information. This is sometimes referred to as a ‘‘knock down’’ 
and allows determining the function of that gene (Herdewijn et al., 1999; Kurreck, 2003).
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Figure  7:  Schematic  diagram  of  oligonucleotide-based triplex  applications.  A: Inhibition  of 
transcription factor binding at a gene promoter; B: Polymerase inhibition; C: DNA strand scission 
by  a  cleaving agent  coupled  to  a  TFO;  D: Site-directed mutagenesis;  E: Triplex-stimulated 
homologous recombination.
TFOs bind in the major groove to the polypurine strand of the duplex DNA via Hoogsteen 
or reverse Hoogsteen hydrogen bonds. The binding to duplex DNA is much slower than 
association of the complementary strands, but quite stable once formed. The electrostatic 
repulsions between the phosphate backbones of the three strands can be reduced by the 
presence  of  divalent  cations  Mg2+,  Zn2+ and  Ca2+,  or  naturally  occurring  amines,  e.g. 
spermine and others seen in Figure 8 (Thomas & Thomas, 1993; Hampel et al., 1991).
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TFOs and their targets are usually 10 30 nucleotides long. The binding can be parallel or‒  
antiparallel to the purine strand of the target sequence depending on the base composition 
of the TFO. In general, pyrimidine-rich TFOs bind parallel and the purine-rich TFOs bind 
antiparallel to the purine strand of the target sequence (Figure 9). In the first, pyrimidine 
motif the protonated cytosines or thymines can bind to the G:C and A:T Watson-Crick base 
pairs,  respectively (Figure 9A). The required protonation of cytosine at N3 needed for 
proper Hoogsteen bond formation with N7 of guanine is one of the major limitations of 
this binding motif. Without the protonation, there is just one hydrogen bond between the 
exocyclic N4 of cytosine and the keto group of guanine. The pKa of a cytosine residue in 
the triplex state is higher than the value of approx. 4.6 for the free nucleotide or in a single 
strand. The value also differs due to the nucleotides position in the triplex (Asensio et al., 
1998). Many mixed sequences containing C+.GC triples have been examined and different 
pKa  values  from  4.6  (Zimmer  et  al.,  1968;  Volker &  Klump,  1994)  to  6.5  (Plum  & 
Breslauer, 1995) have been reported over the years. This was attributed to the different 
local environment. The influence of ionic strength, pH and sequence makes it difficult to 
predict triplex stability for mixed sequences.
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A
(i) C+.GC (ii)   G.GC (iii)   T.AT
 
B 
(i) G.GC (ii)   A.AT (iii)   T.AT
  
Figure 9: A: Chemical structures of parallel triplets: (i) C+.GC, (ii) G.GC, (iii) T.AT; B: Chemical 
structures of antiparallel triplets: (i) G.GC, (ii) A.AT and (iii) T.AT.
Another approach to overcome the pH limitation of the pyrimidine motif is to substitute 
cytosine with 5-methyl-2’-deoxycytidyne, as it has a higher pKa then cytosine. It brings a 
strong  stabilizing  effect  and  expands  the  pH range  compatible  with  triplex  formation, 
which is thought to be due to stacking interactions and water exclusion from the major 
groove (Xodo et al., 1991). A different cytosine replacement, which mimics a protonated 
cytosine residue at physiological pH is 2’-O-methyl pseudo-isocytidine. TFOs containing 
these substitutions have been proven to target the beta-globin gene in living cells (Shahid 
et  al.,  2006).  As mentioned, substantial Mg2+ concentrations are crucial for triple helix 
formation.  Endogenous  concentrations  are  about  1  mM.  To  lower  the  magnesium 
dependency  it  is  also  possible  to  exchange  dT  with  5-(1-propynyl)-2'-deoxyuridine 
(Lacroix  et  al.,  1999).  Another  nucleoside  analog,  2'-O-(2-aminoethyl)-5-(3-amino-1-
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propynyl)uridine, has been proven to stabilize the triplex DNA by reducing the dissociation 
rate,  without  enhancing  the  association  kinetics  (Rusling  et  al.,  2008).  Some  of  these 
nucleotide analogs are commercially available for incorporation into oligonucleotides and 
can be applied for enhancing triplex stability. In 2005 the group of K.R. Fox has developed 
four  nucleotide  analogs  BAU  (2′-aminoethoxy-5-(3-aminoprop-1-ynyl)uridine),  MeP (3-
methyl-2  aminopyridine),  APP  (6-(3-aminopropyl)-7-methyl-3H-pyrrolo(2,
3-d)pyrimidin-2(7H)-one)  and  S  (N-(4-(3-acetamidophenyl)thiazol-2-yl-acetamide)), 
which recognize all 4 bp: AT, GC, CG and TA, respectively. They can form a triple helix 
with mixed sequences at physiological pH and display high binding affinity.
In the second, purine motif G.GC and A.AT base triads are formed (Figure 9B). Unlike the 
pyrimidine motif, the purine-rich TFOs form stable triplexes at neutral pH. Nevertheless, 
the  major  disadvantage  is  the  inhibiting  effect  of  physiological  concentrations  of 
monovalent  cations as  Na+,  but  particularly K+ (Olivas & Maher, 1995;  Cheng & Van 
Dyke, 1993). This effect can be overcome by substitution of T or A by 7-deazaxanthine, 
forming stable  triplets,  applicable  for intracellular  gene targeting (Faruqi  et  al.,  1997). 
Another disadvantage often seen in G-rich TFOs, is that they self aggregate as guanine 
quartets (G-quartets,  Figure 10) and diminish the bioavailability of the oligonucleotides 
(Sen & Gilbert, 1990; Noonberg et al., 1995).
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Figure 10: Structure of G-quartet with metal ion coordination.
The development of many chemically modified nucleotides was driven by the need of 
improved properties, such as enhanced serum stability, greater target affinity and reduced 
toxicity for  in vivo applications (Braasch,  et al.,  2002; Kurreck, 2003). Many forms of 
promising  nucleic  acid  analogs  and  mimics  are  available.  The  most  promising 
modifications  at  the  nucleobase,  sugar  ring  or  the  phosphordiester  backbone  are 
represented  by  peptide  nucleic  acid  (PNA;  Braasch  et  al.,  2002),  locked  nucleic  acid 
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(LNA;  Petersen  &  Wengel,  2003),  phosphorothioates  (Eckstein  et  al.,  2000)  and 
morpholinos  (MO; Taylor  et  al.,  1996).  They are  commercially  available  as  TFOs for 
antisense  therapy  and  have  become  a  general  and  versatile  tool  for  DNA and  RNA 
recognition ( Figure 11).
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Figure 11: Structure of LNA, PNA, phosphorothioates and morpholinos.
TFOs have  been  proven  to  down-regulate  gene  expression by  inhibiting  transcription-
initiation complex formation (Tian  et al.,  2007).  Triple helix-forming ODNs covalently 
linked to an antitumor drug camptothecin could considerably enhance DNA cleavage of 
topoisomerase I and effectively inhibit gene expression (Arimondo  et al., 2006). In the 
group of Albert Pingoud the first steps were made to extend the specificity of a restriction 
endonuclease,  a  single  chain  variant  of  R.PvuII  (scPvuII)  using  TFOs  with  modified 
nucleotides,  5-methyl-2'-deoxycytidine  and  5-(1-propynyl)-2'-deoxyuridine.  The 
specificity of the R.PvuII-TFO conjugate increased about 1000-fold when the cleavage 
reaction was initiated by Mg2+ addition, after the triple helix was formed (Eisenshmidt et 
al., 2005). This approach has not found an  in vivo application, where it is impossible to 
regulate the Mg2+ ion concentration.
1.3.2 Polyamides
At the same time as major groove-binding TFOs were broadly investigated, several groups 
studied DNA-binding  of the  natural  products  netropsin and distamycin (Dervan,  2001; 
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Denny, 2001; Goodsell, 2001). These studies led to the rational design of small synthetic 
polyamides capable of sequence-specific DNA recognition in the minor groove (Burnett et 
al.,  2007).  In  comparison  to  the  triple  helix  approach,  polyamides  are  not  limited  to 
recognition of purines and are proven to have a better cellular uptake. Hydroxypyrrole-
imidazole-pyrrole polyamides (Figure 12) form four ring pairings (Im/Py, Py/Im, Hp/Py 
and Py/Hp), offer a second code to control sequence specificity and can even distinguish 
all  four  Watson-Crick base  pairs  in  the  minor  groove  of  DNA (White  et  al.,  1998). 
However, the disadvantage of polyamides is  that they can target only DNA sequences, 
which are too short to be unique in the human genome.
Figure  12:  Structure  of  N-methyl-3-hydroxypyrrole  (Hp),  N-methylimidazole  (Im)  and  N-
methylpyrrole  (Py)  used  in  polyamides fro  sequence-specific DNA recognition  in  the  minor 
groove.
1.3.3 DNA-binding domains
Until now, the most flexible group of engineered DNA-binding molecules is the group of 
zinc finger proteins (ZFPs). They are the most abundant transcription factors in eukaryotes 
and consist of highly conserved modules (approx. 30 amino acids) where each module can 
bind three or four base pairs. The Cys2His2-type zinc finger is one of the most common 
DNA-binding motifs in eukaryotes. A short sequence of seven amino acids is responsible 
for the protein-DNA interaction and provides an ideal framework for designing proteins 
with new functions. By ‘stitching’ several zinc finger modules together (approximately 6) 
it is possible to target 18 bp, which is unique in the genome sequences. Several genes have 
been up or down regulated by engineered ZFPs fused to activation or repressor domains, 
respectively (Beerli et al., 2000). The expression of P-glycoprotein, a molecule capable of 
transporting drugs out of the cell and causing resistance to chemotherapy, was reduced 
fifteenfold by a hybrid ZFP fused to a KRAB repression domain (Xu et al., 2002). Fusion 
of DNA-binding domains to enzymes, which can interfere with epigenetic gene control 
systems, can cause more permanent silencing of gene expression. Down-regulation of the 
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endothelial growth factor (VEGF-A) expression associated with tumor vessel growth has 
been proven to be a powerful anticancer approach. Partial inhibition was achieved by ZFPs 
fused to a  repressor domain (Snowden  et  al., 2003),  but  also in comparable  levels by 
coupling  the  same  ZFPs  to  the  minimal  catalytic  domain  of  the  histone  H3  MTases 
(Snowden et al., 2002). ZFP were used to regulate gene expression by coupling to DNA 
MTases: M.HhaI and M.HpaII  (McNamara  et  al.,  2002,  Nomura & Barbas  III,  2007), 
M.SssI and M.CviPI (Carvin  et al.,  2003; Xu & Bestor, 1997). Fusion of Dnmt3a/b to 
different binding domains was proven to target methylation of specific regions in gene 
promoters,  via methylation  (Li  et  al.,  2007)  and  the  same  approach  was  applied for 
targeting mitochondrial DNA (Minczuk  et al., 2006). Yet, high background methylation 
has been a drawback of this method. In some cases, unacceptable levels of non-targeted 
methylation at cognate and non-cognate sites of the binding domain were observed (Carvin 
et al., 2003; Li et al., 2007). Fusion of MTases with heterologous DNA binding domains 
often resulted in high background methylation. This can be associated with the fact that 
DNA recognition and catalytic activity are coupled in bacterial MTases (Youngblood et al., 
2006; Nomura & Barbas III, 2007). Therefore, constructing highly specific DNA MTase 
variants is of high importance. One distinct approach based on well studied fusion proteins 
is to compromise the binding affinity of the DNA MTase and let the ZFP domain binding 
dominate, resulting in the desired increased specificity (Smith & Ford, 2007). The most 
recent approach demonstrated by Nomura and Barbas III shows DNA sequence specific 
methylation by two M.HhaI fragments. Both C- and N-terminal domains of the enzyme are 
fused to two zinc finger proteins, each recognizing 9 bp sequences enclosing one M.HhaI 
recognition  site.  Since  the  DNA  MTase  becomes  active  only  after  fragment 
complementation  (Choe  et  al.,  2005),  even  high  level  of  expressed  fusion  proteins 
generated no background methylation at other M.HhaI recognition sites (Nomura & Barbas 
III,  2007). This candid strategy can have great influence on the investigation of DNA-
binding proteins and perhaps it will find application in vivo (Kiss & Weinhold, 2008).
1.4 DNA-protein conjugation methods
Semi-synthetic protein- and peptide-DNA composites have gained much attention in the 
field of nanoscience and bioanalytical chemistry. New protein functions can be applied as 
e.g. molecular scaffolds for constructing protein arrays or supramolecular objects (Wacker 
& Niemeyer, 2004).  Covalent attachment of peptides to DNA has found application in 
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more effective DNA-based technologies. ODNs have been linked to peptides for several 
purposes, such as introducing reporter groups (Tong et al., 1993), for studying peptide-
DNA interactions (Gomez-Pinto  et al., 2003), for preparing nucleases or increasing their 
specificity (Mironova  et al., 2004; Corey  et al.,  1989). Investigation of how metal and 
metal based drugs respond to the proximity of peptides and DNA (Marchan et al., 2004) 
and how to facilitate transport of antisense ODNs through membranes (Rogers et al., 2004) 
has been broadly studied. DNA-protein conjugates have been also used to stablize DNA 
triplex (Tung et al., 1996), or to accelerate duplex formation (Corey, 1995). Despite the 
many applications, synthetic conjugation methods are limited. Most reported bioconjugates 
have been made using bifunctional crosslinkers, which react usually with lysine or cysteine 
residues. The major problem in using thiol- or amine-based chemistry for conjugation is 
the lack of regiospecificity with proteins that hold multiple cysteine or lysine residues. 
Therefore, additional coupling methods have been applied for DNA- or peptide-protein 
conjugation, such as native chemical peptide ligation (NCPL), thiazolidine ligation and 
expressed protein ligation (EPL).
1.4.1 Heterobifunctional crosslinking
Heterobifunctional  crosslinking  is  often  applied  for  coupling  proteins  and  with  DNA. 
There are different kinds of linkers, which can be homo- or heterobifunctional. They are 
chosen depending  on  the  accessibility  of  the  reactive  groups on  the  DNA and protein 
composites. The N-hydroxysuccinimide (NHS) ester is a commonly encountered functional 
group  in  crosslinkers  for  coupling  reactions  with  amino-modified  ODNs.  Amino-
modifications can be introduced by solid-phase DNA synthesis to any ODN. On the other 
end of the bifunctional crosslinkers used for protein-DNA conjugate synthesis are usually 
maleimide groups. These react predominantly with the most nucleophilic cysteine residues 
of the proteins. This is a straightforward method, characterized by mostly desired, high 
yield. Therefore, if there are no available, reactive cysteine residues, or the ones present are 
located e.g. outside the active site, it is usually possible to introduce or remove them by 
site-directed mutagenesis. For enhanced flexibility and solubility, commercially available 
bifunctional  crosslinkers  can  also  contain  polyethylene glycol  (PEG) units  of  different 
length. An example of the described bifuncional crosslinker is the maleimidopropionyl-
PEG27-NHS ester (7, Scheme 5), which has been used for M.SssI-TFO conjugation in this 
study.
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Scheme 5: Structure of maleimidopropionyl-PEG27-NHS ester.
1.4.2 Coupling DNA to the N- or C-terminus of recombinant proteins 
There are few methods for site-specific coupling with recombinant proteins. During native 
chemical peptide ligation (NCPL) an N-terminal cysteine reacts with a thioester  of the 
second molecule, resulting in peptide bond formation. In 1997, Dawson was the first to 
discuss  the  mechanisms  of  this  reaction  (Scheme  6;  Dawson  et  al.,  1997).  The  first 
(thioester-forming)  step  is  reversible,  whereas  the  rearrangement  to  the  amide  is 
irreversible. Site-specificity in this method is obtained by the fact that only the N-terminal 
cysteine residue can rearrange to the thermodynamically stable peptide bond. NCPL has 
been applied for protein synthesis from two short peptides (Dawson et al., 1997), as well as 
peptide-DNA conjugates (Stetsenko & Gait, 2000). 
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Scheme 6: Reaction mechanism for the native chemical peptide ligation (NCPL).
Another coupling method is the thiazolidine ligation, where the N-terminal cysteine reacts 
with an aldehyde group and forms a thiazolidin ring. To avoid non-specific reaction of the 
aldehyde with protein amino groups’ conjugation conditions is performed at slightly acidic 
pH. The mechanism was first reported in the late 1990’s. The aldehyde reacts with the N-
terminal of the second component containing an N-terminal cysteine residue. The free thiol 
attacks the imine under the formation of a thiazolidine ring. This reaction is followed by a 
rearrangement in which the O-acyl ester linkage is transformed to an N-acyl amide linkage 
to  form a  peptide  bond and  a  pseudoproline  structure,  which is  characteristic  for  this 
coupling reaction (Scheme 7; Liu & Tam, 1994). This strategy has been used for peptide-
peptide as well as peptide-DNA coupling (Tam et al., 2001; Forget et al., 2001).  
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The last  method described here is  the expressed protein ligation (EPL).  This approach 
involves  a  recombinant  protein  with  C-terminal  thioester  (or  N-terminal  cysteine), 
prepared by the use of inteins, which can react with other cysteine or thioesters groups 
respectively. Inteins  are  naturally  occurring  group  of  proteins,  associated  with  protein 
splicing. Protein splicing is a posttranslational process that is based on the excision of an 
intervening  polypeptide  sequence,  called  the  intein,  from a  protein  and joining  of  the 
flanking polypeptide sequences, the exteins, by a peptide bond. The mechanism involves a 
series of four intramolecular reactions, where the first three occur at the intein catalytic 
centre (Paulus, 2000).
The  construction  of  intein  proteins  generating  a  C-terminal  thioester  (or  N-terminal 
cysteine) has been known for almost 10 years now (Evans et al., 1999). When the protein 
of interest is fused with the N-terminus of an intein, it is possible to cleave the protein with 
other thiols processing a reactive C-terminal thioester. The commercially available cloning 
24
INTRODUCTION
pCYB vectors for protein expression in E. coli can generate a protein of interest expressed 
in  frame  with  an  intein-chitin  binding  domain  (CBD),  which  facilitates  handling  and 
protein purification (Scheme 8, Muir et al., 1998). For processing an N-terminal cysteine, a 
similar strategy is applied. Fusion proteins contain a CBD on the N-terminus of the extein 
part.  The cleavage of the protein is  forced by pH or temperature change, which is  the 
drawback of this construct, because it can occur spontaneously.
EPL has found broad applications in protein synthesis, protein modifications with small 
molecules  (David  et  al.,  2004)  and  coupling  with  oligonucleotides  (Lovrinovic  & 
Niemeyer, 2005).
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Scheme 8:  Mechanism for creating a C-terminal thioester by fusion to an intein and expressed 
protein ligation (EPL) with a peptide or oligonucleotide (II).
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1.5 Objectives
The purpose of this work was to conjugate the engineered DNA cytosine MTase M.SssI 
with a triple helix-forming oligonucleotide (TFO) and to investigate its  application for 
super-specific DNA methylation. 
M.SssI  is  a  prokaryotic  DNA  MTase,  which  shares  the  recognition  sequence  with 
mammalian DNA MTases and exhibits a high catalytic activity. These properties make it 
an  interesting  model  system  for  assembling  and  studying  the  phenomenon  of  DNA 
methylation in eukaryotes. For super-specific DNA methylation, M.SssI will be conjugated 
to TFO. Targeted DNA methylation could find interesting applications in gene regulation. 
By this means, it would be possible to down-regulate the expression levels of molecules 
associated with disease. In this work, the latent target is the promoter of EpCAM. EpCAM 
is a transmembrane glycoprotein, strongly over-expressed by a variety of carcinomas.
In  the  first  part  of  this  thesis,  two  known  protein-DNA coupling  methods,  namely 
bifunctional crosslinking and expressed protein ligation, are applied for the synthesis of 
M.SssI-TFO conjugates. The second part focuses on the biophysical evaluation of DNA 
binding by the conjugate, which is defined by the combination of the triple helix formation 
and M.SssI DNA binding. The thermodynamics and kinetics of DNA triple helix formation 
could be studied by UV-VIS spectroscopy. The difference in absorbance between duplex 
and triplex DNA, due to a hypochromatic effect upon triplex formation, can be used to 
determine transition points between the various forms of the DNA in thermal denaturation 
processes.  The  same  properties  also  enable  kinetics  measurements  of  triple  helix 
formation. Fluorescence resonance energy transfer (FRET) was applied to investigate the 
orientation of the triplex arrangement. Two fluorophores, one on the end of TFO and the 
other on one end of the duplex, when brought into close proximity give a FRET signal. Its 
appearance is directly correlate with triple helix formation and gives an indication of the 
binding orientation of the third strand to duplex DNA. The binding properties of M.SssI 
alone or with an attached TFO were determined by a 2-aminopurine (2Ap) assay. This 
assay is based on the eviction of 2Ap, located at the target site of the enzyme, from the 
DNA helix,  upon  DNA binding  of  M.SssI.  This  leads  to  a  fluorescence  increase  and 
faithfully reports DNA binding of M.SssI.
Finally, the M.SssI-TFO conjugate was tested in vitro for sequence-specific methylation on 
a plasmid DNA (Litcon54). The test plasmid was designed to carry the triple helix-forming 
site (TFS), which is the binding area for the TFO, together with flanking CpG sites. A 
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restriction assay as well as bisulfite sequencing was used to analyze the CpG methylation 
levels next to the TFS and at non-cognate sites, respectively. 
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2 RESULTS AND DISCUSSION
2.1 Bifunctional crosslinking 
2.1.1 Conjugation of M.SssI(C141S) with TFO
For the conjugation of the low activity vatiant M.SssI(C141S), which possesses only one 
cysteine  residue  on  the  C-terminus  (CT),  with  a  modified  triple  helix-forming 
oligonucleotide  (TFO),  the  heterobifunctional  crosslinking  method  was  applied  
(Scheme 9).  M.SssI(C141S)  was  expressed  and  purified  as  described in  4.4.1 and the 
activity was assayed on λ DNA (4.4.3).
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Scheme 9: Coupling of M.SssI(C141S) with TFO using maleimidopropionyl-PEG27-NHS ester (7) 
as a crosslinker.
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First,  the  TFO  with  a  5’-aminohexyl  linker  (Table  7)  was  modified  with  the 
heterobifunctional  crosslinker  maleimidopropionyl-PEG27-NHS  ester (7)  under  reaction 
conditions described in 4.6.1. The reaction was analyzed by reversed-phase HPLC and the 
final  product  Mal-PEG27-HN-C6-TFO  was  purified  by  the  same  method.  As  seen  in 
Scheme 13 the reaction was almost completed after one hour and further incubation did not 
increase the conversion (not shown). The yield of purified and desalted product was 60%. 
Figure  13:  Reversed-phase HPLC reaction analysis of  H2N-C6-TFO with maleimidopropionyl-
PEG27-NHS ester (7). 1: 0 h; 2: 1 h incubation. 
The coupling reaction between the maleimide group of the modified oligodeoxynucleotide 
(ODN) and the single cysteine residue of M.SssI(C141S) was carried out at 4ºC and pH 7.2 
(4.7.1).  As  reported  before,  the  problem  associated  with  protein  precipitation  can  be 
reduced  by  incubation  at  low  temperatures  (Monami,  2007).  Maleimide  reactions  are 
typically  carried out  at  pH 6.5 7.5 because  at  pH 7.0 the  ‒ reaction of  maleimide with 
sulfhydryl groups proceeds with a 1000 times higher rate than its reaction with amines. At 
pH values over 7.5 non-specific coupling with amines can take place. The modified TFO 
was used in 50% excess over the amount of the enzyme. The reaction was analyzed by 
SDS-PAGE (Figure 14). After 1 h incubation at RT, the reaction was completed and the 
conversion was about 80%. 
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Figure 14: SDS-PAGE analysis of the coupling reaction between M.SssI(C141S) and Mal-PEG27-
HN-C6-TFO. Lane 1: Molecular weight marker; lane 2: 0 h after mixing; lane 3: 0.25 h; lane 4: 
0.5 h; lane 5: 0.75 h; lane 6: 1 h incubation at RT.
Purification of  the  conjugate  was  carried  out  as  reported  before (Monami,  2007).  The 
conjugate and the excess of Mal-PEG27-HN-C6-TFO were bound to the DEAE Sepharose 
Fast Flow (FF) anion exchange column. The positively charged M.SssI(C141S) did not 
bind to this column and passes with the flow through. The elution of the M.SssI(C141S)-
PEG27-HN-C6-TFO conjugate (shortly: M.SssI(C141S)-TFO) and Mal-PEG27-HN-C6-TFO 
from the column was performed as described in  4.7.1. The FPLC chromatogram (Figure
15) displays the elution peak of the conjugate (A) and the excess of TFO (B). The yield of 
the purified and concentrated conjugate was 30%. 
Figure 15:  FPLC chromatogram of the conjugate purification step from the excess of unreacted 
M.SssI and TFO on DEAE Sepharose FF column. A: M.SssI(C141S)-TFO; B: Mal-PEG27-HN-C6-
TFO.
The DNA methylation activity  of  the conjugate  was  tested and compared with that  of 
M.SssI(C141S)  on  λ  DNA (Figure  16).  In  this  modification-restriction  test,  equimolar 
concentrations of M.SssI(C141S) or M.SssI(C141S)-TFO and CpG sites on λ DNA were 
incubated in the presence of the natural cofactor AdoMet (1) over a period of 24 h. During 
this time samples are taken at 1, 2, 4, 8 and 24 h (Figure 16A; M.SssI(C141S)) and 1, 4, 8, 
24  h  (Figure  16B;  M.SssI(C141S)-TFO)  followed  by  restriction  with  the  methylation 
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sensitive  restriction  endonuclease  (REase)  R.BstUI  (4.4.3).  In  both  experiments,  the 
activity is essentially the same after 24 h of incubation, where the DNA is fully protected. 
Conjugation  of  M.SssI(C141S)  with  TFO  was  therefore  possible  without  altering  the 
methylation activity of the enzyme. 
Figure 16: Activity test on λ DNA of A: M.SssI(C141S) and B: M.SssI(C141S)-TFO with cofactor 
AdoMet (1) analyzed by agarose gel electrophoresis. Lane 1: MassRuler DNA Ladder Mix; lane 
2: λ DNA untreated; lane 3: λ DNA after restriction with R.BstUI; lane 4-8: λ DNA incubated with 
M.SssI(C141S)  or  M.SssI(C141S)-TFO  conjugate  and  AdoMet  (1)  for  1,  2,  4,  8,  
24 h followed by incubation with R.BstUI. 
2.1.2 Conjugation of M.SssI with ODN
As mentioned before, heterobifunctional crosslinking is only site-specific if  the protein 
contains one reactive cysteine residue. However, this method becomes non-specific, when 
the  maleimide modified  ODN can  react  with  multiple  present  and  accessible  cysteine 
residues of the enzyme. In the case of M.SssI, encoded by pBH-M.SssI (5.3), this method 
could not be directly applied, because it possesses three cysteines, one in the active site 
(C141) as well as one at the N and C terminus. According to the previously reported data, 
the N terminus cysteine of M.SssI is unreactive (Monami, 2007). However, a modification 
of C141 in the active site is undesired, as it  would block the DNA MTase activity of 
M.SssI. A possible solution to this problem would be to temporarily block the catalytic 
cysteine residue by trapping it in a binary complex with its substrate DNA modified with a 
cofactor analog. It has been shown that M.SssI can modify short duplex ODN containing a 
CpG recognition sequence with the cofactor analog N-adenosylaziridine (Az, 8; Schmidt, 
2004). Under the nucleophilic attack of the DNA, mediated by M.SssI, the aziridine ring 
opens  and  the  whole  cofactor  is  coupled  to  the  C5  position  of  the  target  cytosine  
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(Scheme 10). The stability of the complex is based on the very low dissociation rate of 
M.SssI from the binary complex (M.SssI•DNAAz), however the DNA can be released by 
thermal denaturation.
N
N
N
N
N
H
M.SssI
O
OH OH
N
H
O
OH OH
N
N
N
N
NH2
NH2O
N
N
NH2
O
OO
G
5' 3'
5'3'
O
N
N
NH2
O
OO
G
5' 3'
5'3'
CH3
O
N
N
NH2
O
OO
G
5' 3'
5'3'
N
N
N
N
O
OH OH
NH2
S
H3N CO2
H3C
AdoMet (1)
Az (8)
Scheme 10: M.SssI-mediated methyl group transfer from AdoMet (1) or coupling of the cofactor 
analog Az (8) to the target cytosine within double-stranded DNA.
Cofactor analogs as Az (8), can be used for short-term caging of the M.SssI active site 
cysteine. The formed binary complex of M.SssI and the labeled duplex DNAAz would 
enable site-specific heterobifunctional crosslinking at the C terminus of the enzyme. This 
approach has been tested before by preincubation of M.SssI with an excess of duplex DNA 
and  cofactor  analog,  but  was  unsuccessful,  because  also  coupling  with  the  catalytic 
cysteine  C141  was  detected  (Monami,  2007).  The  reason  for  that  was  that,  despite 
understoichiometric amounts of M.SssI, there was still free enzyme in solution. Clearly, the 
biggest problem was to detect and separate the free M.SssI from M.SssI forming the binary 
complex.  In  this  work  the  cofactor  analog  Az  (8)  was  replaced  by  an
N-adenosylaziridine  derivative  biotinylated  at  the  N6  position  (6BAz,  9;  Figure  17) 
because it could form a more stable complex with M.SssI after reaction with duplex DNA. 
Coupling of the 6BAz (9) cofactor with the target cytosine occurs in analogy to Az (8) 
described above.
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Figure 17: Structure of N-adenosylaziridine biotinylated at the N6 position (6BAz, 9). 
Complex formation could be detected by anion exchange HPLC (Figure 18). M.SssI was 
incubated with the substrate duplex DNA (13_CG+/-,  Table 7) and cofactor 6BAz (9) in 
2:1:10 ratio. The free M.SssI did not bind to the anion exchange column and only the 
duplex and binary complex was detected.
Figure 18: Anion exchange HPLC analysis of trapping M.SssI on duplex DNA6BAz; Incubation at 
37ºC; 1: 0 h; 2: 3 h; 3: 4 h. 
After 4 h of incubation, the complex was purified and the activity of M.SssI was tested in a 
methylation-restriction  assay  (4.4.3).  The  M.SssI·DNA6BAz·complex  was  incubated with
 λ  DNA, an excess of AdoMet (1)  as well as M.HhaI. This DNA cytosine-C5 MTase, 
which recognition sequence 5’-GCGC-3’ overlaps with the 5’-CG-3’ recognition sequence 
of  M.SssI,  binds  with  higher  affinity  to  the  DNA6BAz substrate  than  M.SssI  (data  not 
shown). Its function in this assay was to form a complex with the dissociated DNA6BAz and 
avoid its rebinding by M.SssI. Under these reaction conditions, M.HhaI is also catalytically 
active and methylates the C5 of cytosines within its recognition sequences. To discriminate 
between 5’-CMeG-3’ from 5’-GCMeGC-3’ the restriction step was carried out with CpG-
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methylation  sensitive  R.BsiEI  (5’-CGRYCG-3’ where  R=A  or  G,  Y=C  or  T).  Its 
recognition sequence does not overlap with that of M.HhaI and only recognizes substrate 
sites for M.SssI. Full protection was seen after 24 h of incubation, indicating a very slow 
dissociation rate of the complex M.SssI·DNA6BAz (Figure 19). For comparison, four times 
less free M.SssI  (47.5 ng)  in this activity assay fully methylates the same amount of  
λ DNA within 1 h. This experiment showed the reversibility of the trapping complex.
Figure 19: Activity test on λ DNA of the isolated M.SssI•DNA6BAz complex analyzed by agarose 
gel electrophoresis. Lane 1: λ DNA untreated; lane 2 7: ‒ λ DNA incubated with M.SssI•DNA6BAz 
complex and AdoMet (1)  in  the  presence of  M.HhaI for  1,  2,  4,  6,  8  and 24 h  followed by 
incubation with R.BsiEI.
The HPLC-isolated binary complex of M.SssI•DNA6BAz was coupled to the Mal-NH-C3-
ODN.  Modification  of  the  16-mer  ODN containing  a  5’-aminopropyl  linker  (H2N-C3-
ODN, Table 7) with GMBS (17, 4.6.4) was performed as the modification of TFO with the 
Mal-PEG27-NHS ester (7) described in 2.1.1.
The coupling reaction with the M.SssI binary complex was analyzed by SDS-PAGE after 
0, 0.25, 0.5 and 1 h incubation at RT (Figure 20C) where almost exclusively one reaction 
product  of  conjugation  at  the  CT  of  M.SssI  was  observed.  The  same  reaction  was 
previously carried out on M.SssI twice in the presence of the duplex and cofactor (2:1:10 
ratio) without  HPLC  purification  (Figure  20,  A and  B).  As  shown  in  Figure  18 the 
formation of the binary complex takes time, therefore direct coupling to Mal-NH-C3-ODN 
results in conjugation at the CT and the active site cysteine residues (Figure 20A). After 4 
h  of  preincubation,  of  M.SssI,  6BAz  (9)  and  duplex,  the  conjugation  reaction  occurs 
mostly at the CT, but products at C141 are also visible (Figure 20B). As mentioned above, 
this is due to the fact, that there is also free M.SssI in solution, which can react at the 
catalytic cysteine residue with the Mal-NH-C3-ODN.
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Figure 20: SDS-PAGE analysis of the coupling reaction between M.SssI and Mal-NH-C3-ODN at 
RT.Lane 1: 0 h; lane 2: 0.25 h; lane 3: 0.5 h; lane 4: 1 h incubation. A: in the presence of 6BAz 
(9)  and duplex DNA without preincubation;  B: The same as A, but the coupling reaction was 
initiated after 4 h of preincubation with 6BAz (9) and duplex DNA; C: Coupling with the HPLC 
purified M.SssI•DNA6BAz binary complex.
By this  approach,  the  site-specific  conjugation to the  CT cysteine  of  M.SssI  could be 
achieved and the reversibility of the trapping complex, releasing the catalytic cysteine was 
shown. Yet, isolation of the CT M.SssI-ODN conjugate would demand another purification 
step,  diminishing the overall  yield.  Therefore,  the conjugation reaction was carried out 
with detection by anion exchange HPLC. The trapping reaction of M.SssI with duplex 
DNA and 6BAz (9) (2:1:10 ratio) is shown in Figure 21. After 4 h of incubation there was 
no free duplex DNA anymore. The excess of free M.SssI eluted in the void of this column 
(not shown). After the addition of Mal-NH-C3-ODN and incubation at RT for 1 h the new 
product peak of M.SssI•DNA6BAz-ODN was detected. 
Figure 21: Anion exchange HPLC analysis of trapping M.SssI with duplex DNA and 6BAz (9) at 
RT. After 4 h Mal-NH-C3-ODN was added. 1: 3 h; 2: 4 h incubation; 3: 4 h + 1 h; the excess of 
ODN eluted slightly before the duplex DNA.
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The trapping complex protects exclusively the active site cysteine residue and leads to a 
selective terminal coupling with M.SssI. Despite the fact that the desired product conjugate 
could be successfully detected and isolated (Figure 22), the overall product yield was 2%, 
which lead to a loss of interest in this approach. This low yield was caused by enzyme 
precipitation as well as the inability of M.SssI to form a complex in 1:1 ratio with duplex 
DNA. Excess of protein was needed to modify all of the duplex in solution with 6BAz (9), 
probably because M.SssI was partly inactive or misfolded. Purification of the conjugated 
M.SssI with ODN by HPLC lead to over 50% loss of material and during the following 
concentration step most of the product precipitated.
Figure 22: SDS-PAGE analysis of free M.SssI and purified CT M.SssI-ODN conjugate. Lane 1: 
Molecular weight marker; lane 2: M.SssI; lane 3: CT M.SssI-ODN conjugate.
2.2 Expressed protein ligation
Expressed protein ligation (EPL) is an alternative method of protein-DNA conjugation and 
(1.4.2)  involves coupling of a protein containing a C-terminal thioester with a cysteine-
modified ODN. Among others (native chemical peptide ligation and thiazolidine ligation) 
EPL has been applied for M.SssI-TFO coupling and evaluated before (Monami, 2007). The 
outcome was clearly in favor of EPL. Therefore, in these studies this method has been 
further investigated. 
M.SssI variant Q147L has been found to hold properties of reduced methylation activity 
and much lower binding properties comparing to wild type (wt) M.SssI (A. Kiss, personal 
correspondence). This can be rationalized by its function in the catalytic process of M.SssI 
to supposedly stabilizing the flipped out cytosine in the active center. This low affinity and 
DNA MTase activity mutant, when coupled to a TFO, would make an interesting model for 
studying  TFO-directed  methylation.  In  this  approach  it  is  envisioned  that  the  binding 
affinity of the DNA MTase is compromised and dominated by the TFO component of the 
conjugate. Therefore, the new goal became to couple this variant with the chosen TFO by 
EPL. M.SssI(Q147L) (sequence shown in  5.3) was cloned into an intein vector giving 
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pBAM3-M.SssI(Q147L) and the H2N-C6-TFO was modified to obtain Cys-PEG27-NH-C6-
TFO (16).
2.2.1 Construction of pBAM3-M.SssI(Q147L)
pBAM3-M.SssI(Q147L) has been constructed by the use of the expression vector pBHCC-
M.SssI(Q147L)  and  pBAM3-M.SssI.  The  second  vector,  constructed  by  A.  Monami 
(Monami, 2007), encodes a fusion protein consisting of M.SssI, Mxe GyrA intein, His6 tag 
and  the  chitin  binding  domain  (CBD).  The  selected  DNA  sequence  in  pBHCC-
M.SssI(Q147L) holding the mutation at position 147 was purified from an agarose gel after 
restriction with R.SacI and R.XbaI. pBAM3-M.SssI plasmid was restriced with REases 
and the restricted vector purified with an agarose gel and a QIAquick Gel Extraction Kit. 
Ligation of the two fragments with T4 DNA Ligase gave the desired plasmid pBAM3-
M.SssI(Q147L),  which  was  amplified  and  submitted  to  sequencing  with  the  selected 
sequencing primer (pBH_Seq2_fwd;  Table 5). Exept for the desired mutation, no other 
mutation was observed within the sequenced region of the plasmid. After expression and 
purification  of  M.SssI(Q147L)-thioester  (4.4.2)  the  enzyme  was  frozen  with  liquid 
nitrogen and stored at  -80ºC to prevent  hydrolysis  of  the  reactive thioester. The DNA 
MTase activity of M.SssI(Q147L)-thioester was analyzed with λ DNA and compared with 
the wt M.SssI activity (4.4.3). The activity is lower than that of wt M.SssI by a factor of 3‒
4 (Figure 23).
Figure 23:  Activity test on λ DNA of  A: M.SssI and B: M.SssI(Q147L)-thioester with cofactor 
AdoMet (1) analyzed by agarose gel electrophoresis. Lane 1: λ DNA untreated; lane 2: λ DNA 
after  restriction with R.BstUI;  lane  3 10:‒  λ  DNA incubated with  M.SssI  or  M.SssI(Q147L)-
thioester and AdoMet (1) for 1 h followed by restriction with R.BstUI. In lanes 3-10 the amount of 
DNA MTase is decreased from lane to lane by 50%. 27.8 ng M.SssI (A; lane 7) generates a similar 
restriction pattern as 95 ng of M.SssI(Q147L)-thioester (B, lane 5).
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2.2.2 Synthesis of Cys-PEG27-NH-C6-TFO
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Scheme 11: Synthesis scheme of Cys-PEG27-NH-C6-TFO (16).
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The  purchased  linker  Fmoc-NH-PEG27-COOH  (10)  was  activated  with  
N-hydroxysuccinimide  to  receive  the  Fmoc-NH-PEG27-NHS  (12)  ester  (4.5.1).  The 
reaction was analyzed by reversed-phase HPLC (Figure 24).
Figure 24: Reversed-phase HPLC analysis of Fmoc-NH-PEG27-NHS (12) synthesis. 1: 1 h; 2: 2h 
of reaction time.
After purification of the intermediate Fmoc-NH-PEG27-NHS (12) by reversed-phase HPLC 
it was coupled with H2N-C6-TFO by incubation at 37°C. The Fmoc-NH-PEG27-NHS (12) 
ester  hydrolyzes  with  time  to  the  corresponding  acid  10 and  NHS  (Figure  25,
lane 1). Since an excess of the activated ester was used, almost complete conversion of the 
amino-modified TFO to the desired product Fmoc-NH-PEG27-NH-C6-TFO (13) occurred 
(Figure 25, lane 2). 13 was purified by reversed-phase HPLC, lyophilized to dryness and 
incubated with ammonia at 37°C for over 12 h for Fmoc deprotection of the amino group. 
Again,  the  sample  was  lyophilized  to  dryness,  dissolved  in  water  and  desalted  on  a 
NAP™-5 column. ESI-Q-TOF analysis confirmed the mass of the expected product H2N-
PEG27-NH-C6-TFO (14). The yield was 86%.
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Figure 25: Reversed-phase HPLC analysis of coupling Fmoc-NH-PEG27-NHS (12) with H2N-C6-
TFO.  1: Fmoc-NH-PEG27-NHS (12) before adding H2N-C6-TFO,  2: 2 h reaction,  3:  After 12 h 
deprotection with aqueous ammonia giving the product 14.
The last two steps were coupling H2N-PEG27-NH-C6-TFO (14) with the cysteine modifying 
reagent (CMR, 11) to insert the cysteine moiety and deprotection of the Fmoc protecting 
group. 
Figure  26:  Reversed-phase HPLC  analysis  of  coupling  H2N-PEG27-NH-C6-TFO  (14)  with  
CMR (11). 1: H2N-PEG27-NH-C6-TFO (14) before adding CMR (11), 2: 1 h reaction, 3: After 12 h 
deprotection with aqueous ammonia giving the product Cys-PEG27-NH-C6-TFO (16).
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The needed cysteine modifying reagent CMR (11) was synthesized according to a literature 
procedure (Lovrinovic & Niemeyer, 2005). The final coupling reaction was analyzed by 
reversed-phase  HPLC (Figure  26),  lyophilized  to  dryness  and  the  product  Fmoc-Cys-
PEG27-NH-C6-TFO (15) was incubated with ammonia at 37°C for over 12 h for Fmoc 
deprotection of the amino group. Again, the sample was lyophilized to dryness, dissolved 
in water and desalted on a NAP™-5 column. The product Cys-PEG27-NH-C6-TFO (16) 
was analyzed by ESI-Q-TOF and the yield was 88%.
2.2.3 Effect of linker length on expressed protein ligation
After expression and purification of M.SssI(Q147L)-thioester (4.4.2) its reactivity in the 
EPL reaction was tested. The obstacles of this coupling reaction, mainly low yield and high 
precipitation levels, have been previously investigated (Monami, 2007). Coupling with the 
newly synthetized Cys-PEG27-NH-C6-TFO (16) and the Cys-NH-C3-ODN, without a PEG 
linker, was carried out at pH 8.0 with a tenfold excess of the cysteine-modified TFO or 
ODN in the presence of MESNA (4.7.2) to investigate the influence of the PEG linker on 
the coupling reaction. The difference in reactivity between the two substrates Cys-NH-C3-
ODN and Cys-PEG27-NH-C6-TFO (16) in the EPL reaction with M.SssI(Q147L)-thioester 
can be seen in Figure 27. The two conjugates M.SssI(Q147L)-ODN and M.SssI(Q147L)-
TFO  run  differently  on  the  SDS-PAGE gel  due  to  their  different  molecular  weights. 
M.SssI(Q147L)-TFO has an extra PEG27 linker and the TFO is eight nucleotides longer 
then the ODN (Table 7).
Figure 27:  SDS-PAGE analysis of the EPL coupling reaction between M.SssI(Q147L)-thioester 
and Cys-NH-C3-ODN or Cys-PEG27-NH-C6-TFO (16) at RT. Lane 1: Molecular weight marker; 
lane 2: 0 h; lane 3: 4 h; lane 4: Supernatant after 24 h; lane 5: Precipitant after 24 h.
The reaction of Cys-NH-C3-ODN with M.SssI(Q147L)-thioester lead to a conversion of 
about 30%, which is similar to what was reported before (Monami, 2007). The experiments 
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were carried out at RT for higher coupling efficiency, but as expected, the consequences 
where  seen  in  the  immense  precipitation  levels  (lanes  5).  The  product  conjugates 
(M.SssI(Q147L)-ODN and M.SssI(Q147L)-TFO) as well as the unreacted M.SssI(Q147L)-
thioester were mostly present in the precipitant. Incubation at lower temperatures would 
decreace this negative effect, but a longer reaction time would be needed. Interestingly, the 
various  modifications of  the  two ODNs seem to lead to  a  difference in  reactivity. As 
indicated in  Figure 27, coupling to the Cys-PEG27-NH-C6-TFO (16) resulted in a much 
lower conversion (10%). This effect can be explained by the length and polarity of the 
linker, which could interact with the protein surface, preventing its reaction the C-terminal 
thioester. 
2.3 Super-specific DNA methyltransferase
After analyzing and evaluating method for coupling of M.SssI with DNA, investigating the 
DNA methylation  specificity  of  the  obtained  conjugate  became  the  main  objective  
(Scheme 12). 
Scheme  12: TFO-directed super-specific DNA methylation by M.SssI-TFO conjugate next to a 
triple helix-forming site (TFS).
As mentioned before, EpCAM gene silencing via DNA methylation of its promoter region 
could  find  potential  application  in  gene  therapy  against  many  types  of  carcinomas. 
Therefore, the TFO coupled with M.SssI, was designed to target a selected sequence in the 
EpCAM promoter. The conjugate selectivity was tested in an in vitro assay on the designed 
Litcon54  plasmid  DNA.  Super-specific  methylation  was  analyzed  in  a  restriction-
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modification assay as well as by bisulfite sequencing. In parallel, the triple helix formation 
was  investigated  in  FRET, UV  and  thermal  denaturation  assays,  while  the  binding 
properties of the conjugate were tested by fluorescence spectroscopy.
2.3.1 Design of the TFO
The key aspects of choosing a triple helix-forming site (TFS) were the length and type of 
sequence  (pyrimidine-  or  purine-rich),  but  also  the  proximity  and  importance  of  the 
potential CpG sites. Basing on the promoter sequence (Figure 28), we selected possible 
TFS sites (underlined) and one has been finally chosen based on the length and proximity 
to a CpG sequence. This TFS (underlined and highlighted) has a length of 24 nucleosides, 
which are long enough to be unique in the human genome.
-1967.CTCCTGCCTC AGTCTCCTGA GTAGCTGGGA TTACAGGCGC CCGCCACCAC GCCTGGCTAA CTTCTTGTAT TTTTAGTAGA
 -1887.GACGGGGTTT CACCATGTTG GCCAGGCTGG TCTCGAACTC CTGACCTTAG GTGATCCGCC CGCCTCGGCC TCCCAAAGTG
 -1807.CTGAGATTAC AGGCATGAGC CACCGTACCT GGCCTAAATA CCTTATTTCA TATACCACGT GAAATTTAAA TTATACAAAA
 -1727.CAAATTATAG AGGTACTTAG AACAGCATGA CTATTTACAT TAATCAACTT GCCGGCACTT CAACAGAATA CAACATAGAA 
 -1647.ATGATTGTTT TAATATAAAC ATAAGCTTTG ATTTGACATA TACTTGTAGA AATTAATCAA ACTTAGCTGA ATCTTAAAAT
 -1567.TGCTTTTTTA CCTTTCCTCT TTTTTTTTTA TTTTTTTATT TTTTGAGATG GAGTCTTGCT CTGTTGCCAG ACTGGAGTGC
 -1487.AGCGGTTTGG TCTCGGCTCA CCGCAACCTC CGACTCTCTG GTTCAAGCGA TTCTCCTGCC TCAGCCTCCT GAGTAGCTGG 
 -1407.GATTACAGGT GCCTGCCACC ACACCTGGCT ACTTTTTGTA TTTTTAGTTG AGATGGGTTT CACCATGTTG GCCAGGATGG
 -1327.TCTCGAACTC CTGACCTCGG ATCTGCCCAC CTGTGCCCCC AGCAAGGTGC TGGGATTACA AGCATGAGCC ACCGTGCCCA 
 -1247.GCCTCCTTTC CTCTTTTTAA CTCTTACTTT TATGATTTCT TTAGTGGATA AAAAGCTTTT AAAAAATAGG TTACAATGAT 
 -1167.ATTACAGCTA ACAAAAAATA ACATTTAAAA ACACTAAATA GTATATATAT GAAGTATTTA TAATTATTTT AATATTGTAA
 -1087.TAATATAGTG TGTTGTGATT TGAATTCATC TGCACGGAAA TCGATTACTG TCCTTTCTTT CTATTTCCCT ATATTTTCTT
 -1017.TCCGAAGCGT CATCAACATT TTGGTTCTTT AATAGTAACC AAAACCCGAA ATCATCTCGG TTCTCAGTAT TTGGCTCTAT
  -937.GGGAACACCT TTTC  TTTTCT CTCTTTTTTT TTTTTTTT  GA GACGGAGTCT TGCTCCTGTC GCCCAGGCTG GAGTGTAATG
-857.GCACGATCTC TGCTCACTGC AACCTCAGCC TCCCCAGTAG CTGGGATTAC AGGCATGCGC CACCACGCCC GGCTAATTTT
-777.GTATCTTTTA GTAGAGACGG CGTTCCTCCA TGTTGGTCAG GCTGGTCTCG AACTTCAAAC CTCAGGTGAT CCGCCCGCCT
-697.CGGCCTCCCA AAGTGCTAGG ATTACAGGCG TGAGCCACCG CGCTCAGCCT GGGAACACCT TTTCTTACAT CTTCAAGTGC
-617.TAGAAATGCT TATGAAAACG AAAAAAGAAT TATTAAGAGT AATTATAAAG AAACACTCAT TTTCTTCCCA AGAGAGCCAA
-537.GATTTCTTCT TTCCTCTTCT TTCTTTTTTT TTTCTTTCTA ATTTCAAAGG AGTATAATTA AATTGCCAGG TAAAAGCTCA
-457.AAGGTCTTTT TTATAGTGTT CTGGAAGGTT CTCTGCCTGT GTTTGTATTT CCTTTAGCCT CCACGTTCCT CTATCCAGTT
-377.CCCGCACCCT TCCCCCCAGG CCCCATTCTT CAAGGCTTCA GAGCAGCGCT CCTCCGGTTA AAAGGAAGTC TCAGCACAGA
-297.ATCTTCAAAC CTCCTCGGAG GCCACCAAAG ATCCCTAACG CCGCCATGGA GACGAAGCAC CTGGGGCGGG GCGGAGCGGG
-217.GCGCGCGGGC CCACACCTGT GGAGAGGGCC GCGCCCCAAC TGCAGCGCCG GGGCTGGGGG AGGGGAGCCT ACTCACTCCC
-137.CCAACTCCCG GGCGGTGACT CATCAACGAG CACCAGCGGC CAGAGGTGAG CAGTCCCGGG AAGGGGCCGA GAGGCGGGGC
 -57.CGCCAGGTCG GGCAGGTGTG CGCTCCGCCC CGCCGCGCGC ACAGAGCGCT AGTCCTTCGG CGAGCGAGCA CCTTCGACGC
 +23.GGTCCGGGGA CCCCCTCGTC GCTGTCCTCC CGACGCGGAC CCGCGTGCCC CAGGCCTCGC GCTGCCCGGC CGGCTCCTCG
+103.TGTCCCACTC CCGGCGCACG CCCTCCCGCG AGTCCCGGGC CCCTCCCGCG CCCCTCTTCT CGGCGCGCGC GCAGCATGGC
+183.GCCCCCGCAG GTCCTCGCGT TCGGGCTTCT GCTTGCCGCG GCGACGGCGA CTTTTGCCGC AGCTCAGGAA GGTGAGGCGC
+263.GGATTGGAGC AGAGTTGTGG AGCTGGGCTG GGCTGGGGGG CAGCGGCCCC CGGCCCTCGG CCCCCGAAAC GGGCATAATA
+343.GGGAGGGGAC CAAGAGGCCG CGCTTTCCAG CGTGGAGACC GGACGGTGCG GCCGTGCTCC GGCTCAGGCC CTCCGCGCGG 
+423.TAGGAAACGG CGAGGGCCGT CCCGGGGAGC AGCCTCACTT CGCAGCTTTG CTCGCCTTGG TAGGGAAATG GCCTTGGGCG
+503.GAGGCGGGGG ACAGGCAGGG AACGGAGTGG CCACGTCCAG GTTTCCTGCG GCCACCGAAC CGGTGCCTCG CGCCCTGGCG 
+583.CACCCACGTC CTCGGTTCGG GGTGGACTTG GGGTTCCAAA ACAGCCCCAG CCGGTGGCGG AGTCTTTACG ACAGGGACCA 
+663.GCGGGCTCGC CCTTGTCCTT GCAGCGGGCC CCGGATGTGG GCCTCAGGCG GGGACAGGCGC
Figure  28:  EpCAM promoter sequence and the first intron. The triple helix-forming sites are 
underlined and the chosen one is highlited blue; CpGs are highlighted gray; CpG next to the chosen 
TFS is red.
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2.3.2 In vitro methylation assay on Litcon54
The designed plasmid DNA Litcon54 (Figure 29) holds this TFS sequence (Figure 29, 
marked blue) next to a CpG recognition sequence for M.SssI (marked red). Methylation of 
this target CpG can be identified with the methylation-sensitive restriction endonuclease 
R.Psp1406I.  If  this  CpG  is  not  methylated  R.Psp1406I  cuts  the  plasmid  four  times, 
resulting in four bands (1516, 576, 411, 373 bp) on an agarose gel (Figure 29A). If the 
methylation is super-specific, the target CpG site becomes protected from restriction and 
R.Psp1406I  cuts  only  three  times,  resulting in  three  bands  (2092,  411, 373 bp)  on  an 
agarose gel (Figure 29B). 
The plasmid DNA was incubated with M.SssI(C141S)-TFO conjugate in 1:10 ratio at 30ºC 
in the presence of AdoMet (1). After restriction with R.Psp1406I and analysis by agarose 
gel electrophoresis it was clear that M.SssI(C141S)-TFO conjugate shows super-specific 
methylation at the target CpG, next to the TFS (Figure 29C). By incubation with another 
conjugate preparation in the same 1:10 ratio, the protection at the target site was slightly 
higher, but partial non-super-specific methylation was observed (Figure 30; above the 2092 
bp fragment).
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Figure 29: Super-specific methylation of plasmid DNA (Litcon54). A: Expected restriction pattern 
before and B: after super-specific methylation with M.SssI(C141S)-TFO conjugate. C: Agarose gel 
electrophoresis, lane 1: MassRuler DNA Ladder Mix; lane 2: Litcon54 untreated; lane 3: Litcon54 
after  restriction with R.Pst1406I;  lane 4: after  incubation with  conjugate 0  h;  lane 5: 4  h;  
lane 6: 20 h and restriction with R.Pst1406I.
It  has  been reported,  that  supercoiled and relaxed plasmid  DNA exploits  a  differential 
ability to form intermolecular triplexes (Maxwell et al., 2006). Therefore, both circular and 
linear Litcon54 (L-Litcon54) have been incubated with the M.SssI(C141S)-TFO conjugate 
for  20  h  as  described  before.  The  influence  of  DNA linearization  on  the  degree  of 
protection was negligable. Both L-Litcon54 and Litcon54 were good substrates for TFO-
directed methylation (Figure 30A). Restriction of L-Litcon54 with R.Psp1406I results in 
five bands (1516, 576, 411, 252, 121 bp) on an agarose gel. Because of linearization of the 
373  bp  fragment,  the  121  bp  one  is  invisible.  The  effect  of  conjugate  excess  was 
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investigated  by  incubation  with  different  ratios  of  TFS  to  conjugate  1:1,  1:2  and  1:5 
(Figure 30B). After 20 h reaction of the conjugate followed by restriction with R.Psp1406I 
it  was clear, that more higher conjugate equivalents result in higher methylation at the 
target CpG site (lanes: 4a, 4b, 4c). This might be caused by a slow association rate between 
the conjugate and the TFS (vide infra 2.3.6).
Figure 30:  Super-specific methylation of plasmid DNA (Litcon54) followed by restriction with 
R.Psp1406I.  A: L-Litcon54 vs Litcon54 in 1:10 ratio (TFS:conjugate) analyzed by agarose gel 
electrophoresis (1%).  Lane 1: MW marker;  lane 2: 0 h;  lane 3: 4 h;  lane 4:  20 h incubation.
B: Litcon54 after 20 h incubation in different TFS:conjugate ratios.  Lane 4a: 1:1;  lane 4b: 1:2; 
lane 4c: 1:5.
2.3.3 Bisulfite DNA sequencing
The results from the restriction-modification assay (2.3.2) imply that the M.SssI(C141S)-
TFO conjugate binds and methylates specifically near to the TFS, but gives little indication 
of  possible non-specific  methylation within the  plasmid sequence,  which has over  170 
CpG recognition sites for M.SssI. For a detailed analysis, the large fragment of the DNA 
was scanned for methylated cytosines within the CpG dinucleotide context using bisulfite 
sequencing. Sensitive detection of methylation patterns can be accomplished by the use of 
bisulfite  sequencing,  a  method  based  on  the  different  sensitivity  of  cytosine  and  5-
methylcytosine to deamination  in the presence of  bisulfite  (Wang  et  al., 1980).  Under 
acidic pH, cytosine undergoes conversion to uracil,  while  methylated cytosine remains 
unreactive. The possible incomplete conversion of cytosine to uracil results in appearance 
of false-positive methylation signals and reduces the overall quality of the method. The 
converted  DNA is  amplified  in  a  non-methylation-specific  polymerase  chain  reaction 
(PCR). The produced amplicons are sequenced to detect single nucleotide polymorphisms 
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between C and T. For data analysis the ESME (Epigenetic Sequence MEthylation analysis) 
software was used. The biggest problem during bisulfite sequencing is DNA degradation 
due to depurination, which under conditions, necessary for complete conversion, such as 
high bisulfite concentrations and evaluated temperatures, can come to about 90% (Grunau 
et  al.,  2001).  Nevertheless,  the  primers  design  for  each  amplicon  strongly  affects  the 
overall sequencing outcome. 
Figure 31: Normalized trace file example of a sequenced fragment. Upper case shows the sequence 
after  bisulfite  treatment  and  PCR;  lower  case  is  the  original  aligned  sequence,  
T= thymine, t = converted cytosine. Data from Dr. Reinhold Wasserkort, personal correspondence.
Calculated  percentage methylation is  given  for  cytosines  within  a  CpG position.  Four 
samples of Litcon54 were incubated for 20 h under reaction conditions (4.8.1) with 1, 2, 5 
and 10 equivalents of the M.SssI(C141S)-TFO conjugate and subsequently held at 60ºC for 
20 min for enzyme inactivation. In the case of the first three reactions, samples were taken 
and analyzed in the R.Psp1406I restriction assay (Figure 30). The plasmids were linearized 
with R.ScaI (10 u, 5’-AGTACT-3’) at 37ºC for 1 h. The two controls with wt M.SssI as 
well  as  with 10 eq. conjugate  but  without AdoMet (1)  were handled identically. After 
purification on QIAquick spin columns and elution with Millipore water, the samples were 
submitted  to  bisulfite  sequencing  analysis  at  Epigenomics,  Berlin.  For  200–500  bp 
amplicons (Amp 1, 2, 3, 4a, 4b and 5), shown in  in gray, six forward and reverse primers 
were designed by Dr. Reinhold Wasserkort. It is important that primers should not contain 
any CpG sequences to avoid discrimination between methylated and non-methylated DNA. 
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Amp 1
Amp 2
Amp 3
Amp 4a, 4b
Amp 5
Figure  32:  Litcon54 sequence linearized with R.ScaI. The designed amplicons are indicated in 
gray, all CpGs are marked red, the triple helix-forming site is underlined and bold, target CpG is 
encircled. 
The results obtained from the ESME software (Figure 33 and Figure 34) indicate strong 
methylation  at  the  main  targeted CpG  (#120  in  amplicon  4a  and  b,  Figure  33).  The 
neighboring CpG (#110) is also strongly methylated. This result confirmed our design on 
how the conjugate can bind and methylate. Unfortunately, it was impossible to analyze the 
methylation level of this #110 CpG by the restriction-modification assay, because it is not 
part of a larger recognition site of a methylation-sensitive REase. White spaces indicate 
that no reliable information regarding the methylation of the corresponding CpGs could be 
obtained. The complete ESME shows, that sequencing in some regions, especially over the 
poly-pyrimidine•purine stretch (TFS site), is problematic. Methylation values shown are 
averaged data from sequencing in both directions, but amplicons 4a and 4b for the two 
targeted CpGs could be covered from one side only.
Non-specific methylation seen in the control without cofactor AdoMet (1) can be attributed 
to AdoMet (1) still bound to the conjugate (Figure 34). In general, quantitative data in 
relation to  the  color  code of  methylation levels  need to be interpreted with care.  The 
minimally  enhancing  background  levels,  with  the  growing  number  of  conjugate 
equivalents, points out the selective manner of the process. Only when 10 equivalents are 
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ACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAG
TGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATG
GGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCA
CGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACA
ATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGTGGTTTATTG
CTGATAAATCTGGAGCCGGTGAGCTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGT
ATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCTGAGATAGGTGCCTCA
CTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTACCCCGGTTGATAATCA
GAAAAGCCCCAAAAACAGGAAGATTGTATAAGCAAATATTTAAATTGTAAACGTTAATATTTTGTTAAAATTCGCG
TTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAAT
AGCCCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAA
AGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCAAATCAAGTTTTTTGGGGTCGAGG
TGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCGAACGTGGCGAG
AAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACC
ACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATG
ACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAG
ATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGA
TCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTG
TAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAG
TGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCG
GTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAG
CGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAA
CAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTG
ACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTA
CGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTTA
CACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACC
ATGATTACGCCAAGCTACGTAATACGACTCACTATAGGGCAGATCTTCGAATGCATCGCGCGCACCGTACGTCTCG
AGGAATTCCTGCAGGATATCTGGATCCACGAAGCTTCCCATGGTGACGTCACCGGTTCTAGATACCTAGGTGAGCT
CCTTTTCTTTTCTCTCTTTTTTTTTTTTTTT  GAGACGGAGTCTAACGTTGGTACCCTCTAGTCAAGGCCTATAGTG
AGTCGTATTACGGACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCT
TGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGC
AGCCTGAATGGCGAATGGCGCTTCGCTTGGTAATAAAGCCCGCTTCGGCGGGCTTTTTTTTGTTAACTACGTCAGG
TGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTC
ATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCG
CCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGC
TGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGC
CCCGAAGAACGTTCTCCAATGATGAGCACTTTTAAAGTTCTGCTAGTGGCGCGGTATTATCCCGTGTTGACGCCGG
GCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGT
RESULTS AND DISCUSSION
added non-super-specific methylation becomes visible (Figure 33,  Figure 34). The super-
specific methylation at #110 and #120, next to the TFS, is a clear indication that the TFO-
targeted approach works well. 
Figure  33:  Bisulfite sequencing  results  for  amplicon  4a  and  b.  Below:  Litcon54  fragment 
sequence. Target CpG #110 and #120 are in red boxes, triple helix-forming site (TFS) is indicated 
in blue.
Figure 34: Sequencing data for amplicons 2, 3, 5 and 1.
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2.3.4 Thermal denaturation studies 
Thermal denaturation is  an often applied experiment  for measuring the stability of  the 
DNA ternary  structure  and  can  display  its  thermodynamic  and kinetic  properties.  The 
conformational  changes  induced  by  heat  can  be  detected  based on  the  hypochromatic 
absorbance  shift  at  260  nm  upon  duplex  formation  (Mergny  &  Lacroix,  2003).  This 
spectroscopic method can also be used to study triple helix formation (Plum & Breslauer, 
1995).  In  triplex  melting  curves,  one  can  often  observe  two  transitions.  The  first 
corresponds to the transition from triplex to duplex plus single strand whereas the second 
transition corresponds to the change from associated duplex to unfolded single strands. 
Usually, this process is fast,  occurs over a relatively narrow temperature range and the 
heating and cooling curves superimpose. Triplex formation is 100 1000 fold slower then‒  
duplex formation (Maher et al., 1990) therefore by heating, the slow denaturation will lead 
to  an  overestimation  of  the  Tm.  By  this  transition,  one  can  speak  of  the  hysteresis 
phenomenon  because  neither  the  cooling  nor  heating  curves  correspond  to  the  true 
equilibrium  curve.  Applying  very  low  temperature  gradients  can  bring  the  difference 
between the heating and cooling phase to a minimum. Many groups have investigated the 
role of salt and pH in triplex stability and it is clear, that high divalent ion concentration, 
such as Mg2+, is crucial for triplex stability (Collier et al., 1990; Plum & Breslauer, 1995). 
The chosen 24-mer TFO binds in the parallel orientation to the purine strand of duplex 
30_TFS+/-. 24_TFO has a T-rich sequence and only few cytosines, which makes binding at 
physiological pH possible. The presence of the three C, which need to be protonated to 
form  the  the  C+.GC  triplets  seems,  not  significantly  destabilize  the  triple  helix.  The 
importance of Mg2+ in triplex formation was investigated by thermal denaturation studies 
of the three strands (each 1 µM) after preincubation at 4ºC over night (Figure 35). The 
melting curves at 10 mM Mg2+ show two transition points at 42ºC (triplex) and 66.5ºC 
(duplex). By lowering the Mg2+ concentration to 5, 1 or 0.1 mM, all transitions shift to 
lower temperatures and in the case of 0.1 mM Mg2+ there is no triplex transition to be seen. 
This experiment confirmed the importance and effect of magnesium ion on triple helix 
formation. Moreover, it clearly demonstrated that the 24_TFO is bound to the 30_TFS+/- 
at conditions (30ºC and 10 mM Mg2+), which were used for evaluating the super-specificity 
of the M.SssI(C141S)-TFO conjugate (2.3.2).
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Figure  35: Thermal denaturation of  30_TFS+/- and 24_TFO in  the presence of  various Mg2+ 
concentrations (A: 0.1 mM MgCl2,  B: 1 mM MgCl2,  C: 5 mM MgCl2,  D: 10 mM MgCl2). The 
dashed lines mark the apparent melting temperature for the experiment with 10 mM MgCl2.
2.3.5  Fluorescence resonance energy transfer
Various assays  can be  applied  for  triple  helix  formation analysis  such  as  UV melting 
(2.3.4), circular dichroism (CD) melting, gel electrophoresis, footprint analysis or anion 
exchange  chromatography. Some  of  these  methods  are  heterophasic  and  the  obtained 
signals  do not  directly correspond to triplex formation (Reither  & Jeltsch,  2002).  This 
correspondence  can  be achieved  by  fluorescence  spectroscopic  methods,  such  as 
fluorescence resonance energy transfer (FRET), pioneered by Yang (Yang et al., 1994). 
Many groups have used this homophasic method to analyze the conformation, stability or 
sequence specificity of the triple helix. This method detects the energy transfer between 
two fluorophores, named donor and acceptor. Its efficiency depends on the spectral overlap 
of the donor emission spectrum and acceptor absorption spectrum, the relative orientation 
of the fluorophores, as well as the proximity between them. For the following experiment, 
a double-stranded (ds) DNA (30_ H2N-C6-TFS+/-; Table 7) with a polypurine stretch was 
labeled with the fluorescent probe Alexa 488 and the TFO (H2N-C6-TFO) single strand was 
labeled with Alexa 555. As control, the polypyrimidine strand of the TFS duplex was also 
coupled with Alexa 488. All modifications were done on the 5’-amino-linked ODN ends, 
using standard succinimidyl-ester labeling chemistry. The FRET between this fluorophore 
pair  was  expected  to  be  efficient,  because  of  a  high  F rster  radius  of  70  Å  ӧ
(7  nm).  For  the  control  experiment,  where  the  estimated  distance  between  the  two 
fluorophores is about 100 Å (for 27 nucleotides with estimated distance of 3.4 Å each), 
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there was no change in fluorescence intensity when the polypyrimidine strand and TFO 
were 5’-labeled with Alexa 488 and 555.
A               B
    
Figure 36: A: Principle of the FRET assay. B: Fluorescence intensity change of the donor Alexa 
488 for the labeled polypurine (gray) or polypyrimidine (black) strand.
Using the FRET assay it was possible to confirm the parallel binding orientation of the 
TFO with respect to the polypurine strand of the duplex. Thus, the desired triple helix via 
Hoogsteen  hydrogen  bonds  was  obtained.  Only  in  this  orientation,  an  efficient  super-
specific DNA methylation of CpG #110 and #120 is expected.
2.3.6 Kinetics and thermodynamics of triple helix formation
For biological application of different DNA-binding modules, as TFOs, polyamides and 
ZFPs, tight binding characterized by low dissociation constants is needed to have an effect 
on the target gene. Binding is generally measured on free DNA and not  in vivo and the 
correlation between the experimental dissociation constants (Kd)  and endogenous gene-
expression has to be investigated. The Kd reported for PNA or ZFPs is usually at low nM 
values,  e.g.  G-rich  PNA to a  quadruplex-forming sequence derived  from the  promoter 
region  of  the  MYC proto-oncogene  binds  with  a  Kd =  5  nM  (Roy  et  al.,  2007).  ZF-
transcription factors (ZF-TFs) engineered to bind and influence the luciferase reporter gene 
showed an effect when the Kd was about 10 nM and was relatively inefficient when the Kd 
exceeded 30 nM (Zhang et al., 2000). The functional binding selectivity of ZF-TSs to the 
addressed vs. unaddressed promoter sequence (both sequences shared 15 of 18 bp) could 
be associated with the Kd values of 1 nM and 10 nM, respectively (Beerli et al., 2000). To 
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be able to compete with cellular DNA-binding proteins, like RNA polymerases and TFs, 
TFOs should bind their targets in a highly specific manner, while non-specific interactions 
should be weaker and characterized by fast dissociation. Triple helices are thought to be 
formed via a nucleation zipper mechanism, in which the first few productive triplets form 
fast and the rest of the bases wrap around the double helix fast (Alberti  et al., 2002). It is 
known that triplex association is very slow. With a rate constant about 103 M-1s-1 it is three 
orders of magnitude slower than duplex formation (James et al., 2003; Paes & Fox, 1997). 
This reflects the requirement of assembling three polyanionic strands and strongly depends 
on  the  ionic  strength  (Rougee  et  al.,  1992).  The  stabilizing  effect  of  monovalent  and 
divalent ions, especially Mg2+, has been investigated broadly. It is of importance that too 
high monovalent ion concentrations can destabilize the triplex by reducing the equilibrium 
binding  constant.  This  destabilization  can  be  reversed  by  increasing  the  divalent  ion 
concentrations, e.g. Mg2+ (Maher et al., 1990). The dissociation rates of triple helices are 
also very slow. For different sequences,  the reported half-lives  are from 30 min up to 
several  days  (Maher  et  al.,  1990;  Rougee  et  al.,  1992;  James  et  al.,  2003).  For  the 
investigated 24-mer TFO, a relatively long T-rich sequence (Table 7), the association rate 
constants  (kon)  were  measured  by  the  UV assay  for  various  Mg2+ concentrations.  As 
mentioned before the hypochromicity change of absorption at 260 nm takes place upon 
triple helix formation. In these experiments, the process was initialized by adding Mg2+ to 
the solution of 30_TFS+/- ds and 24_TFO ss. 
Figure 37:  UV absorption change at 260 nm upon triplex formation at 5 mM (left) and 10 mM 
Mg2+  (right)  between 250  nM  30_TFS+/-  duplex  and  375  nM 24_TFO.  Black  lines  display 
analytical curve fittings according to monoexponential binding model. 
By identifying the association constants it was possible to show that the DNA sequences 
chosen for the TFS and TFO display good binding properties and, as expected, decreasing 
the  Mg2+ concentration  reduced  the  association  rate  constants:  kon(10  mM  MgCl2)  =
21100 M-1s-1,  kon(5 mM MgCl2)  = 8000 M-1s-1 (Figure 37)  and kon(2.5 mM MgCl2)  =  
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4300 M-1s-1 (data not shown). These data are consistent with the fluorescence assay using 
thiazole orange (TO) as intercalator (data not shown). 
The estimation of Kd values for triple helix formation have been made in our group by 
Dipl.-Chem. Matthias Bahr, using the fluorescent TO as intercalator. This sensitive method 
allow investigation of DNA concentrations as low as 1 nM is based on the fact that TO 
binds to the double helix, staining it fluorescently (Petty  et al., 2000). Upon triple helix 
formation, initiated by adding the third strand or Mg2+ the fluorescence intensity increases. 
The  measured  kinetics  were  very  slow  and  only  a  few  measurements  were  made. 
Estimations of the Kd value could be made by using simulation curves with set Kd and 
amplitudes. According to the model with one binding equilibrium, the estimated Kd was 
about 0.5 nM (Figure 38).
Figure 38: Fluorescence intensity change upon tripe helix formation. A: black lines display curve 
simulations with the same set amplitudes according to a  model with one binding equilibrium.
A: Kd = 5 nM; B: 500 pM: C: 50 pM. 
2.3.7 Protein-DNA interactions
Apart  from investigating  the  kinetic  and  thermodynamic  properties  of  the  triple  helix 
formation, interaction between M.SssI(C141S) and DNA is of importance to understand 
the super-specificity of M.SssI(C141S)-TFO conjugate.  M.SssI,  as other  DNA MTases, 
when  initially  bound  to  its  substrate  DNA,  is  thought  to  work  by  a  base  flipping 
mechanism, where the target base is flipped out of the double helix for catalysis. This 
property can be used to analyze the binding of M.SssI to DNA by exchanging the target 
cytosine  in the  5’-CG-3’ recognition sequence by  the  fluorescent  probe 2-aminopurine 
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(2Ap, Figure 39). The fluorescence of 2Ap is quenched by base stacking interactions in the 
double  helix.  When  M.SssI  binds  to  the  target  sequence,  2Ap  is  flipped  out  and  its 
fluorescence  increases.  This  2Ap fluorescence assay is  commonly used for  monitoring 
DNA binding of DNA MTases (Holz et al., 1998). Here it was also applied to investigate 
M.SssI-DNA interactions.
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Figure 39: Structures of adenine and 2-aminopurine.
The binding of M.SssI(C141S) to 2Ap-modified 25-mer duplex DNA (25_2Ap+/-) was 
investigated (4.8.3). The stabilizing effect of Mg2+ for the triple helix formation is in the 
case of enzyme binding not observed. In contrary, it weakens the M.SssI(C141S) binding 
to the 2Ap duplex, which could be seen in the fitted dissociation constants Kd < 0.1 nM and 
Kd = 8.6 nM for binding in the absence or presence of 10 mM Mg2+, respectively (Figure
40). Mg2+ reduces the binding affinity, by presumably working as a competitor for M.SssI. 
It  shields  the  negative  charge  of  the  duplex,  which  is  important  for  protein-DNA 
interactions. Yet, it was surprising to see, that the conjugate in the presence of 10 mM Mg2+ 
displayed  weaker  binding  affinity  than  M.SssI(C141S)  in  the  same  conditions.  The 
25_2Ap+/- duplex titrated with the M.SssI(C141S)-TFO conjugate gave an even smaller 
fluorescence increase than M.SssI alone (Figure 40,  diamonds).  It  is not clear how CT 
enzyme conjugation with the ss TFO via a long PEG27 linker can interfere with binding of 
M.SssI(C141S) to its substrate DNA. Altered binding properties did not seem to influence 
the  DNA MTase activity  of  this  mutant  when conjugated with  TFO,  as  shown in  the 
restriction-modification assay in  Figure 16. The reason for that can be the difference in 
buffers as well as much higher concentrations used in the restriction-modification assay. 
The calculated dissociation constants are given for M.SssI(C141S) binding to the 2Ap/G 
base pair mismatch introduced in the M.SssI recognition sequence. Therefore, they must be 
interpreted with caution and knowing, that this M.SssI variant binds to this mismatch pair 
at least one order of magnitude better than its 5’-CG-3’ sequence (Figure 41). 
55
RESULTS AND DISCUSSION
Figure 40: Fluorescence intensity change of 2-aminopurine upon binding of M.SssI(C141S) to a 
2Ap-modified duplex (triangles:  10  mM Mg2+;  squares:  0  mM Mg2+)  or  M.SssI(C141S)-TFO 
conjugate (diamonds: 10 mM Mg2+). The black lines display analytical curve fittings according to 
one binding equilibrium.
experiments were carried out in the presence of 10 mM Mg2+. The analytical fitting curve 
A corresponding  to  Kd =  9.7  nM,  whereby  titration  in  the  presence  of  13_CG+/-  as 
competitor did not affect the binding to 25_2Ap+/- (Figure 41, triangles). The simulated 
fitting  (curve  B)  for  the  same amplitude as  A,  but  considering  two binding equilibria 
between the M.SssI(C141S)•25_2Ap+/- and M.SssI(C141S)•13_CG+/- and set values of 
Kd = 9.7 nM (25_2Ap+/- ) and Kd = 100 nM (13_CG+/-) indicates the strong preference in 
binding to the mismatch-holding duplex. 
Figure  41: Fluorescence intensity change of 2-aminopurine upon binding of M.SssI(C141S) to 
25_2Ap+/- duplex (250 nM) in the presence (triangles) and absence (squares) of 13_CG+/- duplex 
(1000 nM). The analytical fitting curve A, according to a model with one binding equilibrium with 
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The two titrations of 25_2Ap+/- duplex (250 nM), with M.SssI(C141S) in the presence or 
absence of the competitive 13_CG+/- duplex (1000 nM) are shown in  Figure 41. Both 
the K = 9.7 nM for M.SssI(C141S)· 25_2Ap+/-. The fitting curve B simulates the same titration d  
d  according to a model with two binding equilibria and with a set K = 100 nM.
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Even though,  the obtained Kd  values are not  given for M.SssI(C141S) binding to the  
5’-CG-3’ sequence,  they can  give  a  general  overview of  the  binding properties  of  the 
conjugate  vs.  the  enzyme  itself  and  evaluate  the  significance  of  change  in  reaction 
conditions  (Mg2+).  The  binding  affinity  of  M.SssI(C141S)  decreased  drastically  after 
conjugation with TFO, but the in vitro assay on Litcon54 (Figure 30) as well as bisulfite 
sequencing ESMA data (Figure 33) could prove super-specific DNA methylation of the 
conjugate. This clearly indicates that binding of the conjugate to DNA is dominated by 
binding  of  the  TFS,  which  is  a  request  for  super-specific DNA methylation.  Because 
the conjugate binding to the plasmid DNA was impossible, another approach was made. 
Scheme 13: Principle of M.SssI(C141S)-TFO conjugate binding to the 45_2Ap duplex holding the 
Based on the Litcon54 sequence, a 45-mer duplex (45_2Ap+/-) was constructed holding 
the TFS as  well  as  an adjacent target site  for the M.SssI  with  a  2Ap/G mismatch,  to 
investigate the binding of the conjugate in the proximity of the TFS. The binding of TFO 
to the TFS, should lock the enzyme near to its target site and facilitate the binding to the 
flanking recognition sequence (Scheme 13). The new 45_2Ap+/- (100 nM), as well as the 
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modifying Litcon54 with a 2Ap/G mismatch at the target site (Figure 32) and  analyzing 
target 2Ap/G site, next to the TFS. 
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25_2Ap+/-  (100  nM)  duplex  were  titrated  with  M.SssI(C141S)-TFO conjugate  in  the 
presence of 10 mM Mg2+ (Figure 42). 
Figure 42: Fluorescence intensity change of 2-aminopurine upon binding of M.SssI(C141S)-TFO 
conjugate to 45_2Ap+/- duplex (filled squares) and 25_2Ap+/- duplex (open squares).
The titrations clearly show that the enzyme part of the conjugate binds much better to its 
target sequence when it is located in proximity of the TFS. The nucleobase composition in 
the two investigated duplexes (25_2Ap+/- and 45_2Ap+/-) next to the enzyme’s recognition 
sequences is different but, as reported before, this does not influence the binding of M.SssI 
(Rathert et al., 2007). This new observation explains the super-specificity of the conjugate, 
as well as low non-specific methylation levels, shown by the restriction-modification assay 
and bisulfite sequencing (Figure 29, Figure 33 and Figure 34).
2.3.8 Cell delivery
To evaluate the true potential of biologically active substances they must be tested in living 
organisms, initially in cell lines and then in animals. There are different ways of bringing 
molecules through the cell membrane into the cytoplasm or further into the cell nucleus, 
which mostly depend on the nature of the transported molecule. Ideally, this process should 
be  highly  efficient,  specific  and  lead  to  as  little  cell  damage  as  possible.  Very often, 
specific types of viruses are used for DNA import, but their biggest disadvantage is that 
they invoke strong immunogenic response. Another DNA delivery method, which usually 
does not invoke immunogenic response, uses transfection agents. They consist of cationic 
lipids or polyethylenamines. One often used transfection agent is  the  amphiphilic lipid 
SAINT-2  (N-methyl-4-(dioleyl)-methylpyridinium  chloride),  containing  a  pyridinium 
group,  with a  positive charge and two alkyl  chains  attached to a  methane in  the  para 
58
RESULTS AND DISCUSSION
position. Although SAINT-2 can deliver siRNA or DNA into the cell alone, it is usually 
mixed  with  the  lipid  helper  DOPE  (dioleoylphosphatidylethanolamine)  in  1:1  ratio  as 
SAINT-2:DOPE  1:1  (SD).  Transfection  with  SD  is  serum  insensitive  and  has  found 
application in transfecting nucleotides and proteins (profection), regardless to their size or 
charge (van der Gun et al., 2007). This delivery system has also been used for profection 
with M.SssI, which was capable of actively silencing the endogenous EpCAM expression 
via DNA methylation (van der Gun et al., 2008). Alternative transmembrane drug delivery 
systems use protein transduction domains (PTDs) or cell-penetrating peptides (CPPs). This 
requires fusing the protein of interest with a short peptide, which has the ability to cross 
biological membranes in a non-disruptive way without apparent toxicity. CPPs can also 
deliver low weight drugs, imaging agents, oligonucleotides or peptides (Foged & Nielsen, 
2008). 
As  mentioned  before,  successful  profection  of  M.SssI  with  SAINT-2:DOPE  1:1  and 
intracellular  methylation led to a down-regulation of the methylation sensitive EpCAM 
gene and demonstrated nuclear uptake. Yet high background methylation levels obtained 
this way are lethal for cells and the EpCAM derived M.SssI(C141S)-TFO conjugate should 
be a solution to this problem. Because producing bigger amounts of this conjugate needed 
for profection experiments is time consuming and expensive, another approach was taken 
to evaluate the power of sequence-specific methylation in the EpCAM promoter region. A 
constructed  plasmid  p39E,  holding  the  promoter  of  EpCAM  upstream  of  a  sequence 
encoding the green fluorescent protein (GFP) was incubated with the five equivalents of 
M.SssI(C141S)-TFO conjugate under conditions described for super-specific methylation 
of  Litcon54  (4.8.1).  As  a  control,  the  same  plasmid  was  incubated  with  wt  M.SssI 
methylating  the  p39E  completely. After  purification,  the  plasmids  were  submitted  to 
bisulfite  sequencing.  Subsequent  transfection experiments  were  carried  out  on SKOV3 
cells followed by detection of GFP expression levels. The transfection experiments were 
done independently two times in triplicate. As explained before, the TFO was designed to 
bind to a sequence within the EpCAM promoter. If TFO-directed, selective methylation of 
p39E would influence gene expression as expected, it could result in GFP down-regulation. 
The primary data interpretation obtained from the collaborating group of Dr. Marianne G. 
Rots at the UMCG in Groningen, were very promising. Transfection with p39E treated 
with the conjugate resulted in GFP down-regulation up to 35% of the maximum level 
observed with the thoroughly methylated p39E with wt M.SssI and correlates to previously 
reported intracellular EpCAM silencing via M.SssI methylation (van der Gun et al., 2008). 
This shows the imposing influence of  single site  methylation  on gene expression. These 
59
RESULTS AND DISCUSSION
promising results set a good background for further in vivo research on testing the effect of 
the M.SssI(C141S)-TFO conjugate methylation on the endogenous EpCAM expression.
There have been many investigations on EpCAM regulation and carcerogenesis (1.2.5) and 
among those,  several  controversial  reports  involving  its  expression  in  correlation  with 
cancer invasiveness, tumor progression and bad patient survival were published (Songun et 
al., 2005; Spizzo  et al., 2006). These reported findings suggest that dynamic change of 
EpCAM expression levels is regulated in the process of tumor invasion and metastasis 
(Shiah et al., 2008) and make further investigations in the field of EpCAM regulation even 
more compelling.
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3 SUMMARY AND OUTLOOK
3.1 Summary
In this work, an engineered variant of the DNA cytosine-C5 methyltransferase (MTase) 
M.SssI  has been conjugated with a triple  helix-forming oligonucleotide  (TFO) and the 
properties of the enzyme-TFO conjugate were evaluated using a variety of biochemical and 
biophysical methods. M.SssI is the only known prokaryotic DNA MTase which shares the 
5’-CG-3’ recognition sequence (CpG) with mammalian DNA MTases. It has been rendered 
a super-specific MTase by conjugation with a TFO designed to bind a triple helix-forming 
site (TFS) in the promoter of the  epithelial cell adhesion molecule (EpCAM) with high 
specificity  and  affinity. This  transmembrane  glycoprotein  is  strongly  overexpressed  in 
several  carcinomas  and  its  expression  levels  have  been  shown  to  correlate  with  the 
EpCAM promoter methylation status (van der Gun et al., 2008). EpCAM down-regulation 
via  sequence-specific DNA methylation could find potential application in gene therapy. 
Three M.SssI variants have been selectively conjugated with DNA single strand, either by 
bifunctional crosslinking or expressed protein ligation (EPL). Only one conjugate has been 
further investigated, as a tool for super-specific TFO-directed DNA methylation. 
M.SssI(C141S) has been conjugated with the chosen TFO using a well known maleimide 
based bifunctional crosslinking method. In M.SssI(C141S), the catalytic cysteine has been 
replaced with serine and thus it possesses only one C-terminal cysteine residue, which can 
be  crosslinked with  the  TFO  via a  long polyethylaene  linker  (Mal-PEG27-TFO).  After 
purification  by  DEAE  anion  exchange  chromatography  the  overall  yield  of  the 
M.SssI(C141S)-TFO conjugate was 30%.
Wild type M.SssI, which possesses more than one cysteine residue, has been coupled with 
an oligodeoxynucleotide (ODN) also by heterobifunctional crosslinking, but in a longer 
synthetic  route  featuring  the  temporary  protection  of  the  active  site  cysteine  (C141). 
Coupling with catalytic  cysteine could lead to a loss of DNA MTase activity. Therefore, 
M.SssI was incubated with a short substrate duplex DNA and the cofactor analog 6BAz 
(9).  The  trapping  and  subsequent  conjugation  reaction  was  analyzed  and the  desired  
C-terminally ODN-linked conjugate could be purified by anion exchange HPLC. However, 
the obtained overall yield was 2%, which excluded this approach to obtain larger amounts 
of M.SssI-ODN conjugate, from further investigations. Trapping M.SssI is a good way to 
temporally  block  the  catalytic  cysteine  residue,  but  can  be  applied  only  to  variants 
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displaying good binding properties. Isolating the formed trapping complex can be also seen 
as a selection of the catalytically active M.SssI molecules from the misfolded or inactive 
ones and way to determine the amount of active enzyme in the preparation. This approach, 
despite a very low yield, enabled conjugation and purification of an ODN-comjugate with 
catalytically  active  M.SssI.  Such discrimination is  infrequent  in DNA-protein  coupling 
methods. 
Finally, coupling of the low binding variant M.SssI(Q147L) with the TFO was carried out 
by  EPL.  The  C-terminal  thioester  and  a  cysteine  modified  TFO,  needed  for  the  EPL 
reaction  had  to  be  prepared.  Similar  to  the  Mal-PEG27-NHS,  used  for  bifunctional 
crosslinking  of  M.SssI(C141S),  a  PEG27-containing  linker  was  chosen  to  add  spatial 
flexibility  to the  M.SssI(Q147L)-TFO conjugate.  It  was  designed to be coupled to the 
5’-amino-linked TFO and the cysteine modifying reagent  CMR (11),  which inserts the 
cysteine moiety needed for EPL. Coupling of M.SssI(Q147L)-thioester with the TFO was 
analyzed by SDS-PAGE and resulted in 10% conversion. The previously reported 30% 
conversion of M.SssI-thioester into an M.SssI-ODN conjugate (Monami, 2007) was also 
obtained  when  the  M.SssI(Q147L)-thioester  was  ligated  with  the  same  ODN,  not 
containing the long  PEG linker. Applying EPL for producing the M.SssI(Q147L)-TFO 
conjugate  was not  successful  in  terms of  high conversion.  This  and high precipitation 
levels reduced the usefulness of this method for producing M.SssI(Q147L)-TFO conjugate 
in an amount needed for testing TFO-directed super-specific DNA methylation in vitro.
The  specificity  of  M.SssI(C141S)-TFO  conjugate  obtained  by  heterobifunctional 
crosslinking has been tested in an in vitro methylation assay on Litcon54. This test plasmid 
was designed to hold  the  corresponding TFS for  the  TFO, next  to  a  CpG recognition 
sequence  for  M.SssI,  which  methylation  status  could  be  identified  by  a  methylation-
sensitive R.Psp1406I DNA restriction endonuclease (REase). The results showed super-
specific  DNA methylation  of  the  targeted  CpG  site.  In  addition,  the  effect  of  DNA 
supercoiling  on  the  super-specific  methylation  was  investigated,  but  no  detectable 
differences were observed. The result of incubating Litcon54 with different ratios of the 
conjugate (1:1, 1:2, 1:5, and 1:10) was that the higher the excess, the more methylation at 
the target site was observed in the restriction modification assay.
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For a more detailed methylation status analysis, Litcon54 was treated with the conjugate in 
the above mentioned TFS:conjugate ratios and then scanned for methylated cytosine within 
the CpG dinucleotide context using bisulfite treatment. The analysis confirmed the super-
specific, TFO-directed DNA methylation and showed that background DNA methylation 
levels were only slightly elevated even in the sample with the highest conjugate excess. 
In  parallel  to  analyzing  the  super-specific  methylation  of  the  M.SssI(C141S)-TFO 
conjugate, the thermodynamic and kinetic properties of triple helix formation were studied. 
The chosen TFO is a polypyrimidine T-rich strand, which binds in a parallel orientation to 
the polypurine strand of the duplex DNA.  The influence of magnesium on triple helix 
formation was analyzed by thermal denaturation, showing that increasing the magnesium 
ion concentration had a stabilizing effect. In addition, the fluorescence resonance energy 
transfer (FRET) assay was used to confirm the binding orientation of the TFO to the TFS. 
The kinetics of triple helix formation were analyzed in the UV assay. In correlation with 
the  thermal  denaturation  studies,  the  stabilizing  effect  of  higher  magnesium  ion 
concentration (up to 10 mM) could be associated with increased association rates for the 
triple helix formation. In addition, an effect on the dissociation rate is expected.
DNA binding affinity of M.SssI(C141S) and M.SssI(C141S)-TFO was investigated in the 
2-aminopurine (2Ap) fluorescence assay, which is based on the eviction of 2Ap, located at 
the target site of the enzyme, from the DNA helix, upon DNA binding of M.SssI. In this 
assay a negative effect of magnesium ions on the DNA binding affinity of M.SssI(C141S) 
was observed. Magnesium ions shield the duplex DNA and neutralize its negative charge, 
which  is  crucial  for  DNA-protein  interactions.  Moreover,  the  M.SssI(C141S)-TFO 
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conjugate  displayed  a  much  reduced  DNA  binding  affinity  in  comparison  to 
M.SssI(C141S). Yet, when a DNA substrate with the TFS sequence next to the target site 
was  investigated,  the  DNA  binding  of  the  enzyme  within  the M.SssI(C141S)-TFO 
conjugate could be significantly restored.
The imposing effect of a single methylated 5’-CG-3’ sequence  by M.SssI(C141S)-TFO 
conjugate on  gene expression was shown in transfection experiments. SKOV3 cell were 
transfected  with  a  conjugate-treated  reporter  plasmid  p39E,  possessing  the  EpCAM 
promoter  sequence  upstream  of  the  green  fluorescent  protein  (GFP)  gene.  Selective 
methylation resulted in GFP expression down-regulation of 35% compared with the fully 
methylated plasmid. 
3.2 Outlook
In this work it was shown, that single site-specific methylation can have an effect on gene 
expression.  The  results  obtained  in  the  transfection  experiments  with  the  selectively 
methylated reporter plasmid were the first evidence that one super-specificly methylated 
CpG of the EpCAM promoter sequence is 
capable  of  partially  reducing  gene 
expression.  Whether  this  was  a  result  of 
methylation  spreading  occurring  on  the 
plasmid when brought into the cell, is still to 
be investigated. 
To estimate the potential of M.SssI(C141S)-
TFO for endogenous gene down-regulation 
one  needs to keep in  mind,  the  enormous 
differences between  in vitro optimized and 
in vivo occurring conditions. It is difficult to 
predict whether the conjugate, when brought 
into  the  cell  by  profection,  would  remain 
stable  and  if  so,  would  it  reach  and 
methylate its target site in the tangled and 
constantly  changing  chromatin  structure. 
The  upcoming  profection  experiments  for 
endogenous EpCAM down-regulation will be the next stage of the project and show the 
true potential of this approach. 
64
SUMMARY AND OUTLOOK
In this work, super-specific DNA methylation by the M.SssI(C141S)-TFO conjugate has 
been demonstrated. It can be envisioned as a basis for a general novel gene regulating 
system. The power of TFOs to direct any DNA-binding protein to a single site  in the 
human genome would open the door to a new class of drugs in epigenetic therapy.
.
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4 EXPERIMENTAL
4.1 Materials
4.1.1 Chemicals
All used chemicals were purchased in the highest purity available (p.a.) from the following 
companies.
Table 1: List of chemicals.
Product Company
Acetic acid KMF (Lohmar)
Acetonitrile (HPLC grade Ultra) J.T. Baker (Griesheim)
Acrylamide-bis-solution (37,5:1) Serva (Heidelberg)
Agar AppliChem (Darmstadt)
Agarose Invitrogen (Karlsruhe)
Ammonia solution (33%) J.T. Baker (Griesheim)
Ammoniumperoxosulfate (APS) Serva (Heidelberg)
Ampicillin sodium salt AppliChem (Darmstadt)
Amylose resin New England Biolabs (Frankfurt a.M.)
L-(+)-Arabinose Fluka (Taufkirchen)
Boric Acid Gerbu (Gaiberg)
Bradford reagent Pierce (Bonn)
Bromphenol blue sodium salt Serva (Heidelberg)
Chitin beads New England Biolabs (Frankfurt a.M.)
Coomassie Brilliant Blue R250 Serva (Heidelberg)
N,N'-Diisopropylcarbodiimide (DIC) Fluka (Taufkirchen)
N,N-Dimethylformamide (DMF) Merck (Darmstadt)
Disodium hydrogen phosphate Merck (Darmstadt)
1,4-Dithio-DL-threitol (DTT) Fluka (Taufkirchen)
Fmoc-Cys-(tButhio)-OH Novabiochem (Darmstadt)
Fmoc-NH-PEG27-COOH Novabiochem (Darmstadt)
Ethanol Merck (Darmstadt)
Ethidium bromide Sigma (Taufkirchen)
Ethylenediaminetetraacetic acid (EDTA) Gerbu (Gaiberg)
D-Glucose Gerbu (Gaiberg)
Glycerol, 99% Sigma (Taufkirchen)
Glycerol, water-free, 99,5% Gerbu (Gaiberg)
Glycine Gerbu (Gaiberg)
Guanidinium hydrochloride Gerbu (Gaiberg)
HEPES Gerbu (Gaiberg)
His Select HC Nickel Affinity Gel Sigma (Taufkirchen)
Hydrochloric acid, 37% Merck (Darmstadt)
N-Hydroxysuccinimide Fluka (Taufkirchen)
Imidazole Fluka (Taufkirchen)
Isopropanol Merck (Darmstadt)
Magnesium chloride hexahydrate J.T. Baker (Griesheim)
4-maleimidobutyryloxy-succinimide ester (GMBS) Fluka (Taufkirchen)
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Mal-PEG27-NHS LCC (Switzerland)
2-Mercaptoethanol Serva (Heidelberg)
2-Morpholino-ethanesulfonic acid (MES) Gerbu (Gaiberg)
2-Mercaptoethanesulfonic acid sodium salt (MESNA) Fluka (Taufkirchen)
Potassium dihydrogen phosphate J.T. Baker (Griesheim)
Potassium chloride Merck (Darmstadt)
Sodium acetate (water-free) J.T. Baker (Griesheim)
Sodium dihydrogen phosphate J.T. Baker (Griesheim)
Sodiumdodecylsulfate (SDS) Gerbu (Gaiberg)
Sodium chloride Gerbu (Gaiberg)
Sodium hydroxide J.T. Baker (Griesheim)
SYPRO Red Protein Gel Stain Sigma (Taufkirchen)
Tetrahydrofuran (THF) Acros (Geel)
N,N,N',N'-Tetramethylethylenediaminen (TEMED) Acros (Geel)
Tris(2-carboxyethyl)phosphine hydrochloride Acros (Geel)
Tris base Gerbu (Gaiberg)
Tris hydrochloride Gerbu (Gaiberg)
Triton X-100 Fluka (Taufkirchen)
Tryptone BD Biosciences (Heidelberg)
Mal-PEG27-NHS LCC (Egerkingen, Schweiz)
N-Succinimide Fluka (Taufkirchen)
Yeast extract BD Biosciences (Heidelberg)
The  cysteine-modifying  reagent  (CMR,  11)  was  synthesized  according  to  Lovrinovic 
(Lovrinovic & Niemeyer, 2005).
4.1.2 Enzymes
The commercially available enzymes were purchased from the following companies:
Table 2: List of enzymes.
Enzyme Company
Proteinase K Qiagen (Hilden)
R.BsiEI New England Biolabs (Frankfurt/M.)
R.BstUI New England Biolabs (Frankfurt/M.)
R.KpnI New England Biolabs (Frankfurt/M.)
R.NcoI MBI Fermentas (St. Leon-Rot)
R.Psp1406I MBI Fermentas (St. Leon-Rot)
R.PstI MBI Fermentas (St. Leon-Rot)
R.SacI MBI Fermentas (St. Leon-Rot)
R.ScaI Jena Biosciences (Jena)
R.XbaI MBI Fermentas (St. Leon-Rot)
T4 DNA ligase MBI Fermentas (St. Leon-Rot)
4.1.3 DNA and  plasmids
Except for Litcon54 all DNA, plasmids and markers were purchased.
67
EXPERIMENTAL
Table 3: List of DNA and markers.
Product Company
λ DNA MBI Fermentas (St. Leon-Rot)
MassRuler DNA Ladder, Mix MBI Fermentas (St. Leon Rot)
O'GeneRuler 500 bp DNA Ladder MBI Fermentas (St. Leon-Rot)
Protein MW marker MBI Fermentas (St. Leon-Rot)
Litmus28i NEB (Frankfurt/M)
Plasmids encoding M.SssI
The pBH-M.SssI, pBHCC-M.SssI(C141S) and pBHCC-M.SssI(Q147L) were constructed 
by  Prof.  Dr. A.  Kiss,  Dr. K. Slaska-Kiss  and  Dr. T. Raskó (Institute  of  Biochemistry, 
Biological  Research Center  of  the  Hungarian Academy of  Science,  Szeged,  Hungary). 
pBAM3-M.SssI  was  constructed  by  Dr. A.  Monami  and  pBAM3-M.SssI(Q147L)  was 
constructed for the purpose of this thesis.
Table 4: Pasmids encoding the M.SssI mutants.
Plasmid Encoded enzyme
pBH-M.SssI M.SssI
pBHCC-M.SssI(C141S) M.SssI(C141S)1
pBHCC-M.SssI(Q147L) M.SssI(Q147L)
pBAM3-M.SssI M.SssI-Y-Mxe GyrA-CBD-His6
pBAM3-M.SssI(Q147L) M.SssI(Q147L)-Y-Mxe GyrA-CBD-His6
1 The sequence is different then of M.SssI(C141S) used by Dr. A. Monami (Monami, 2007)
Primers and oligonucleotides
All primers and oligonucleotides, except for 45_2Ap+/- (IBA, Göttingen) were purchased 
from Eurogentec, Cologne.
Table 5: Names and sequences for sequencing primers.
Name Sequence
pBH_Seq2_fwd 5'-CACTATCTTGGAATTCAAAAAATCC-3'
Litmus28i_fwd 5'- CTGCAGGATATCTGGATCCAC-3'
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Table 6: Names and sequences for cloning primers.
Name Sequence
54_TFS+ 5'-CCTTTTCTTTTCTCTCTTTTTTTTTTTTTTTGAGACGGAGTC
TAACGTTGGTAC-3'
54_TFS- 5'CAACGTTAGACTCCGTCTCAAAAAAAAAAAAAAAGAGAGA
AAAGAAAAGGAGCT-3'
Table 7: Names and sequences of oligonucleotides.
Name Sequence
45_2Ap+ 5'-CCTTTTCTTTTCTCTCTTTTTTTTTTTTTTTGAGA2ApGGAGTCT
AA-3'
45_2Ap- 5'-TTAGACTCCGTCTCAAAAAAAAAAAAAAAGAGAGAAAAGAA
AAGG-3'
30_H2N-C6-TFS+ 5'-Aminohexyl-TTCTTTTCTCTCTTTTTTTTTTTTTTTGAG-3'
30_H2N-C6-TFS- 5'-Aminohexyl-CTCAAAAAAAAAAAAAAAGAGAGAAAAGAA-3'
30_TFS+ 5'-TTCTTTTCTCTCTTTTTTTTTTTTTTTGAG-3'
30_TFS- 5'-CTCAAAAAAAAAAAAAAAGAGAGAAAAGAA-3'
25_2Ap+ 5'-TACAGTATCAGG2ApGCTGACCCACAA-3'
25_2Ap- 5'-GTTGTGGGTCAGCMeGCCTGATACTGT-3'
13_CG+ 5'-TGTCAGCGCATGA-3'
13_CG- 5'-TCATGCMeGCTACA-3'
H2N-C3-ODN 5'-Aminopropyl-GCTCTGCTGCATGCCG-3'
H2N-C6-TFO 5'-Aminohexyl- TTTTTTTTTTTTTTTCTCTCTTTT -3'
24_TFO 5'- TTTTTTTTTTTTTTTCTCTCTTTT-3'
4.1.4 Escherichia coli strains
The  E.  coli cells  ER1821  were  obtained  from  New  England  Biolabs  (Frankfurt/M.). 
Genotype  F-  glnV44  e14-(McrA-)  rfbD1?  relA1?  endA1  spoT1?  thi-1  Δ(mcrC-
mrr)114::IS10.
The  E. coli cells DH5α were provided internally. Genotype F- φ80lacZΔM15Δ(lacZYA-
argF) U169 deoR recA1 endA1 hsdR17(rk-, mk+) phoAsupE44 thi-1 gyrA96 relA1 λ-.
4.1.5 Instruments
Agarose gel electrophoresis
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Agarose  gel  electrophoresis  was  carried  out  in  the  Sub-Cell  GT  Agarose  Gel 
Electrophoresis System connected to a Power Pac 300 System from BioRad (Munich).
Centrifugation
Eppendorf  tubes were centrufuged in an Eppendorf Centrifuge 5410. Cell  cultures and 
lysates were centrifuged in  an Avanti J-20 High-Performance Centrifuge from Beckman 
(Munich) with rotors JS-4.3 and JA-17. 
Cell opening
E.  coli cell  disruption  was  performed  by  sonication  with  a  Ultraschall-Desintegrator 
Sonifier II W-250 from Branson (Dietzenbach). During the cell disruption procedure the 
cells were kept on ice and treated 10 × 10 s at output 8 and 60% duty cycle with 1 min 
pause between each pulse. 
Electroporation
MicroPulser from BioRad (Munich) was used for electroporation procedures.
Incubation
For incubations at temperatures above 60ºC a Heat Block HBT 130 from HLC (Bovenden) 
was used. For other incubations a Heraeus Function Line from Kendro (Hanau) or Mini-10 
incubator from MWG-Biotech was used.
Lyophilization
Lyophilization was carried out in a Speed Vac Plus SC 110A with a refrigerated Vapor 
Trap RVT 100 from Savant.
pH determination
For pH determination  a pH-Meter 766 Calimatic from Knick (Berlin) was used together 
with an IJ44 pH electrode from Gamma Analysen Technik (Bremerhaven).
Sterilization
For sterilizing liquids and equipment a Varioklav steam sterilizer form H+P Labortechnik 
(Dülmen) was used.
Shaker
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E. coli cells were incubated in an incubator shaker Innova 4330 from New Brunswick 
Scientific.
Centrifugation
Centrifugation was performed with an Eppendorf Centrifuge 5415D.
SDS Polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was carried out in  a Mini-PROTEAN 3 Cell connected to a Power Pac 300 
System from BioRad (Munich). For drying SDS-PAGE gels the Gel Dryer, model 583 
from BioRad (Munich) was used.
Water purification system
Water (HPLC grade) was  purified with an ELIX 3 Water System and passage through a 
Milli-Q Academic water-purification system from Millipore (Eschborn).
4.2 Methods
4.2.1 DNA sequencing 
Plasmid DNA sequencing was performed at the Fraunhofer Institute for Molecular Biology 
and Applied Ecology (Aachen).
4.2.2 HPLC
Reversed-phase HPLC (high performance liquid chromatography) was carried out with a 
Waters Breeze System, consisting of a binary pump system Waters 1525, a Waters 2487 
Dual λ absorbance detector and a Waters inline degasser. The total system was controlled 
by the Breeze Software from Waters (Eschborn) running on Windows XP. Chromatography 
was performed at room temperature (RT).
The purification of oligonucleotides and reaction control was carried out on a  reversed-
phase  HPLC NC Prontosil C-18 column (250 ×  4.6 mm, 5  μm, 120 Å) from Bischoff 
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(Leonberg) at 1 ml/min flow. Purification of trapping complexes and reaction controls were 
carried out with an anion exchange Poros 10 HQ column (100 × 4.6 mm) from PerSeptive 
Biosystems (Framingham) at 4 ml/min flow. All buffers were microfiltrated before use 
(0.2 µm, HPLC filters, Whatman, Dassel) and all samples were applied to the column in a 
dilute water solution. Absorption detection was carried out at λ = 260 nm and 280 nm. 
The following buffer systems were used:
Gradient 1: 0 20 min‒ 15% 50% B‒
20 32 min‒ 50% 100% B‒
32 42 min‒ 100% B
42 44 min‒ 100% 15% B‒
Buffer A: 100 mM TEAAc, 1 mM NaN3, pH 7.0
Buffer B: 100 mM TEAAc, 1 mM NaN3, 70% CH3CN, pH 7.0 
Gradient 2: 0 10 min‒ 5% 50% B‒
10 30 min‒ 50% 100% B‒
30 35 min‒ 100% B
32 33 min‒ 100% 5% B‒
Buffer A: 50 mM TEAAc, 1 mM NaN3, pH 7.0
Buffer B: 50 mM TEAAc, 1 mM NaN3, 90% CH3CN, pH 7.0 
Gradient 3: 0 5 min‒ 20% B
5 10 min‒ 20% 50% B‒
10 22 min‒ 50% 100% B‒
22 28 min‒ 100% B
28 30 min‒ 100% 20% B‒
Buffer A: 10 mM Tris HCl, 1 mM NaN3, pH 7.6
Buffer B: 10 mM Tris HCl, 1 mM NaN3, 1 M KCl, pH 7.6,
4.2.3 FPLC
A Pharmacia Biotech FPLC (Fast Protein Liquid Chromatography) system consisting of a 
LCC-500  Plus  Chromatography  Controller,  two  High  Precision  Pumps  P-500  and  a 
fraction  collector  FRAC-100  was  used  for  protein  and  protein-ODN  purification.  The 
following columns were used: the POROS HS 50 cation exchanger (16 × 90 mm and 26 × 
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42  mm,  Applied  Biosystems,  Weiterstadt)  and  DEAE  Sepharose  Fast  Flow  anion 
exchanger (16 × 13 mm, Amersham Pharmacia Biotech, Freiburg). Before use the columns 
were equilibrated with 10 column volumes (cv) of the starting buffer. Purifications were 
performed at 4°C.
4.2.4 ESI-Q-TOF 
The  mass  of  modified  oligonucleotides  was  measured  by  ESI-Q-TOF  (Electrospray 
ionisation-quadrupole-time of  flight)  (Waters, Micromass)  at  the  Centre  d’Analyse  des 
Residus en Traces (CART), University of Liege, Belgium.
4.2.5 UV-Vis absorption spectroscopy
UV-Vis absorption  spectroscopy  measurements  were  carried  out  with  a  UV-Visible-
Spectrophotometer Cary 3E from Varian (Darmstadt). 
4.2.6 Fluorescence spectroscopy
Fluorescence  measurements  were  carried  out  with  a  CARY  Eclipse  Fluorescence 
Spectrophotometer from Varian (Darmstadt) equipped with a thermo-controlled cell holder. 
For the 2-aminopurine assay the excitation and emission wavelengths were set to λEx = 320 
nm  and  λEm =  384  nm.  Excitation  and  emission  band  width  were  5  nm  and  
10 nm, respectively. Measurements were performed at 25°C. Curve fittings according to a 
model with one or two binding equilibrium were done as reported elswere (Bahr  et al., 
2008).
4.3 Molecular biology methods
4.3.1 Agarose gel electrophoresis
Agarose (0.35 g) was mixed with 0.5  TBE buffer (35 ml, 44.5 mM Tris Base, 44.5 mM 
boric acid, 1 mM EDTA, pH 8.0) containing ethidium bromide (0.5 µg/ml) and dissolved 
by  heating  in  a  microwave  oven.  The  warm  solution  (1%)  was  poured  into  an 
electrophoresis chamber. After the gel  solidified samples were supplemented with 6   
loading buffer (1.5 v/v, 0.25% bromphenol blue, 30% glycerol) and loaded into the wells. 
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0.5   TBE buffer with  ethidium bromide  (0.5  µg/ml)  was  added,  the  electrophoresis 
chamber was closed and a current (100 V) was applied for 45 min. Finally, the DNA was 
visualized by UV light (λ = 312 nm) and a Polaroid picture of the gel was taken.
4.3.2 Gel filtration
NAP-5 columns from Amersham Pharmacia Biotech (Freiburg) were used for gel filtration 
of  DNA or protein solutions. The columns were equilibrated with water (10 ml) and the 
sample solutions (500 μl) were applied. Elution was carried out with water (1 ml).
4.3.3 SDS-PAGE
Gel  electrophoretic  analysis  of  proteins  was  carried  out  by  the  SDS-PAGE (sodium 
dodecyl sulfate polyacrylamide gel electrophoresis) Leammli protocol. The Laemmli gels 
are composed of two different gels, the stacking (5%) and the running gel (15%), where 
each of them has a different pH. The upper stacking gel concentrates the protein samples 
before they enter the lower running gel. 
The running (ca. 5 ml) gel was prepared by mixing acryl amide/bisacrylamide (2.5 ml, 
37.0, 5:1, 30%), 4   running gel buffer (1.25 ml, 1.5 M Tris HCl, 0.4% SDS, pH 8.8), 
water (1.25 ml), APS (25 µl, 100 mg/ml) and TEMED (2.5 µl). The solution is directly 
applied between two glass plates and covered with isopropanol to prevent the gel from 
drying out. The polymerization is complete in ca. 20 min. Isopropanol is removed and the 
stacking  gel  is  applied.  The  stacking  gel  (ca.  1.5  ml)  was  prepared  by  mixing  acryl 
amide/bisacrylamide (250 µl, 37.0, 5:1), 4  stacking gel buffer (375 µl, 0.5 M Tris HCl, 
0.4% SDS, pH 6.8), water (875 µl), APS (12 µl, 100 mg/ml) and TEMED (1.5 µl). Protein 
samples mixed with an equal volume of 2  SDS buffer (2% SDS, 10% glycerol, 50 ppm 
bromphenol blue, 640 mM 2-mercaptoethanol), incubated at 95°C for 5 min and applied to 
the gel. Electrophoresis is carried out at 150 V in 1   SDS running buffer (25 mM Tris 
HCl, 200 mM glycine, 0.1% SDS, pH 8.3) for 80 min. Afterwards the gels were stained 
with  Coomassie  Brilliant  Blue  (10%  acetic  acid,  40%  ethanol,  50%  water,  0.05% 
Coomassie Brilliant Blue R250). After staining, the gels were incubated in the destaining 
solution (10% acetic acid, 40% ethanol, 50% water) until the protein bands become visible. 
Gels were transferred into water and washed a few times and finally dried on paper in a 
vacuum drier. Gels after SYPRO Red staining (0.02% SYPRO Red in 7.5% acetic acid) 
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were washed with 7.5% acetic acid for 1 min and then transferred into water. Polaroid 
pictures were taken under UV light (λ = 312 nm).
4.3.4 Determination of protein concentration
Measurements  of  protein  concentration  were  done  according  to  the  Bradford  method 
(Bradford, 1976). Protein solutions were filled up to 100 µl with water and mixed briefly 
with 900 µl of Bradford’s reagent. After 10 min the absorption was measured at 595 nm 
and the protein concentration calculated according to a BSA calibration curve.
Alternatively the absorption was determined at 280 nm in UV-Puffer (50 mM NaH2PO4,
6 M guanidinium HCl, pH 6.5) and the concentration was determined according to the 
molar extinction coefficient, calculated by the ProtParam program (Gasteiger et al., 2005) 
on the Expasy homepage (www.expasy.com).
4.3.5 Determination of DNA concentration
DNA concentration was calculated from the measured by UV absorption at  λ = 260 nm. 
The solution was diluted in  water  and the  absorption was measured in a  1  cm quartz 
cuvette  at  RT. The  molar  extinction  coefficients  were  calculated  with  the  nearest-
neighbour method  (Cantor  et  al.,  1970).  For  the  2Ap  containing  strands  the  molar 
extinction coefficient of free 2Ap riboside (ε260 = 1700 M-1cm-1) was used (Ward, et al., 
1969).  Concentration of  double-stranded DNA was verified according to  the  empirical 
formula 1 OD260 = 50 ng/µl. As an alternative method, small DNA amounts were visually 
compared with the MassRuler DNA Ladder Mix on the agarose gel.
4.3.6 Amplification and isolation of plasmid DNA
LB medium (10 ml) with ampicillin (100 µg/ml) and glucose (0.2%) was inoculated with 
one colony of cells containing the plasmid of interest (see 4.3.8) and incubated overnight at 
37°C and 250 rpm. On the next day the cells were harvested at 4°C for 10 min and 3700 g 
(4000  rpm).  Plasmid  DNA was  isolated  from the  cell  pellet  using  the  QIAprep  Spin 
Miniprep Kit (Qiagen, Hilden) according to the instructions of the manufacter.
4.3.7 Preparation of electrocompetent E. coli cells
All centrifugation and washing steps were done at 4°C, or on ice. LB medium (200 ml) 
was inoculated with an overnight culture (2 ml) and incubated up to an OD600 of 0.5-0.6 at 
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37°C and 250 rpm. Afterwards, the cell culture was centrifuged for 15 min at 2800 g  
(3500  rpm).  The  supernatant  was  decanted  and  the  cell  pellet  resuspended  in  a  10% 
glycerol (100 ml) solution. The cells were centrifuged again and the cell pellet was newly 
resuspended in a 10% glycerol (100 ml) solution. The procedure was repeated twice, but 
resuspension was done first in 10% glycerol (10 ml) and then in 10% glycerol (800 µl). 
Finally aliquots (40 µl) were frozen in liquid nitrogen and stored at -80°C.
4.3.8 Transformation by electroporation
Competent  E. coli cells (4.3.7; 40 µl) were slowly thawed on ice for 30 min and mixed 
with plasmid DNA (5 ng) solution, with which they were to be transformed, and incubated 
on ice for 1 min. The cells were moved into a cooled electroporation cuvette (1 cm) and 
exposed to an electric pulse with an intensity of 1.8 kV. The cells were directly mixed with 
LB medium (1 ml) and incubated for 1 h at 37°C and 200 rpm. Finally 100, 200 and 400 µl 
of cell suspensions were plated on LB/Amp/0.2% glucose plates and incubated at 37°C 
overnight.
4.3.9 Construction of Litcon54
The commercially available vector Litmus28i (2 µg) was digested with R.SacI and R.KpnI. 
For that need Litmus28i was incubated for 1 h at 37°C in NEBI buffer (10 mM Bis-Tris-
Propane HCl, 10 mM MgCl2, 1 mM DTT, pH 7.0), with 0.1 mg/ml BSA, R.SacI (50 u) and 
R.KpnI (50 u). The vector fragment was purified by agarose gel electrophoresis (1% gel) 
and extracted from the gel with the QIAquick Gel Extraction Kit (Qiagen, Hilden). The 
insert was produced by hybridization of 54_TFS+ and 54_TFS- (see  4.1.3;  Table 6) in 
buffer (15 µl, 40 mM Tris HCl, 10 mM MgCl2, 10 mM DTT, 1 mM ATP, pH 7.5). Finally, 
the vector fragment (30 ng) and insert (40 ng) were incubated at 16°C for 16 h in buffer 
(10 µl) with T4 DNA Ligase (1 u). Afterwards the solution was incubated at 60°C for  
20 min and the DH5α cells were transformed with the DNA, as described in 4.3.8. 
4.3.10 Construction of pBAM3-M.SssI(Q147L)
pBAM3-M.SssI(Q147L) plasmid was obtained by introducing a mutation in the M M.SssI-
Y-Mxe GyrA-CBD-His6 vector  via casette  mutagenesis.  The  insert  was  derived  from 
pBHCC-M.SssI(Q147L). Both pBAM3-M.SssI and pBHCC-M.SssI(Q147L) were digested 
with R.SacI and R.XbaI in parallel.
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For that purpose the vectors (1 µg) each were incubated at 37°C 1 h in NEB4 buffer (1 µg, 
50  mM KOAc,  20  mM Tris HOAc,  10  mM Mg(OAc)2,  1  mM DTT,  pH 7.9)  with  
0.1 mg/ml BSA, R.SacI (10 u) and R.XbaI (10 u). The insert from pBHCC-M.SssI(Q147L) 
was purified by agarose gel electrophoresis (1.5% gel) and extracted from the gel with the 
use  of  the  QIAquick  Gel  Extraction  Kit  (Qiagen,  Hilden).  The  vector  fragment  from 
pBAM3-M.SssI was purified by agarose gel electrophoresis (0.7% gel) and extracted from 
the gel as described above. Finally, the vector fragment (30 ng) and insert (40 ng) were 
incubated at 16°C for 16 h in buffer (15 µl, 40 mM Tris HCl, 10 mM MgCl2, 10 mM DTT, 
1 mM ATP, pH 7.5) with T4 DNA Ligase (1 u). Afterwards the ligation solution the T4 
DNA Ligase was incubated at 60°C for 20 min and the ER1821 cells were transformed 
with the DNA, as described in 4.3.8.
4.4 Protein purification and activity assays
4.4.1 Purification of M.SssI, M.SssI(C141S) and M.SssI(Q147L)
LB medium (10 ml) with ampicillin (100 µg/ml) and glucose (0.2%) was inoculated with 
one colony carrying the desired plasmid pBH-M.SssI, pBHCC-M.SssI(C141S) or pBHCC-
M.SssI(Q147L)  and  incubated  over  night  at  37°C and  250 rpm.  On  the  next  day  LB 
medium (5   200 ml)  with ampicillin  (100 µg/ml)  was  inoculated with  the overnight 
culture (each 2 ml) and incubated up to OD600 of 0.7 0.9 at 37°C and 225 rpm. The protein‒  
expression was induced by adding to each of five cultures a 25%  L-arabinose solution  
(8 ml) and incubation for 3 h at 30°C and 225 rpm. The process cells were harvested by 
centrifugation at 4°C and 3700 g (4000 rpm) for 30 min and stored at -20°C.
All following steps were carried out at 4°C or on ice. The wild type as well as C141S and 
Q147L were purified on separate columns. The cells were resuspended in buffer (5 ml 
buffer per 1 g cells,  50 mM NaH2PO4,  300 mM NaCl, 1 mM imidazole,  pH 8.0) and 
disrupted  by  sonication.  After  centrifugation  at  39800  g  (17000  rpm)  for  1  h  the 
supernatant  was  applied  at  a  1  ml/min  flow to  a  His-Select  Nickel  Affinity  column  
(1 1.5 ml), earlier equilibrated with buffer (10 ml, 50 mM NaH‒ 2PO4, 300 mM NaCl, 1 
mM imidazole, pH 8.0).  The column was washed with 10 cv of the same buffer. The 
protein  was  eluted  with  10  cv  of  buffer  (50  mM NaH2PO4,  300 mM NaCl,  250  mM 
imidazole,
pH 8.0). The salt concentration of the eluate was diluted to 200 mM by adding 50% v/v of 
buffer (6.7 mM NaOAc, 6.7 mM MES, 6.7 mM Hepes, 1 mM EDTA, 10% glycerol,  
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pH 7.5) and applied to a cation exchange column (20 ml, Poros HS 50). After washing the 
column with 5 cv of buffer (0.2 M NaCl, 6.7 mM NaOAc, 6.7 mM MES, 6.7 mM Hepes,
1 mM EDTA, 10% glycerol, pH 7.5) the protein was eluted with a linear NaCl-gradient 
(0.2 1 M) in the total volume of 10 cv. All three protein variants eluted at 640 800 mM‒ ‒  
NaCl salt concentration. The collected fractions (each 2.11 ml) were analysed by SDS-
PAGE. Fractions containing M.SssI, M.SssI(C141S) and M.SssI(Q147L) were individually 
pooled and concentrated by ultrafiltration (Jumbosep 10K and Amicon Centriprep YM-10) 
to a  volume of 500 µl,  mixed 1:1 with glycerol  (water-free) and stored at -20°C. The 
amounts of the purified proteins were 3.8 mg (M.SssI),  3.4 mg (M.SssI(C141S)), and  
4.2 mg (M.SssI(Q147L)).
4.4.2 Purification of M.SssI(Q147L)-thioester
LB medium (10 ml) with ampicillin (100 µg/ml) and glucose (0.2%) was inoculated with 
one E.coli colony carrying the pBAM3-M.SssI(Q147L) plasmid and incubated over night 
at  37°C  and  250 rpm.  On  the  next  day  LB  medium (5   200  ml)  with  ampicillin  
(100 µg/ml) was inoculated with the overnight culture (each 2 ml) and incubated up to 
OD600 of 0.7 0.9 at 37°C and 225 rpm. Protein expression was induced by adding to each‒  
of the five cultures a 25% L-arabinose solution (8 ml) and incubation at 30°C for 3 h and 
225 rpm. Cells were harvested by centrifugation at 4°C and 3700 g (4000 rpm) for 30 min 
and stored at -20°C.
All following steps were carried out at 4°C or on ice. The cells were resuspended in buffer 
(5 ml buffer per 1 g cells, 50 mM NaH2PO4, 300 mM NaCl, 1 mM imidazole, pH 8.0) and 
disrupted  by  sonication.  After  centrifugation  at  39800  g  (17000  rpm)  for  1  h,  the 
supernatant was applied to the His-Select Nickel Affinity column (1 1.5 ml), equilibrated‒  
with buffer (50 mM NaH2PO4, 300 mM NaCl, 1 mM imidazole, pH 8.0) at a 1 ml/min 
flow. The column was washed with 7 cv buffer (50 mM NaH2PO4, 300 mM NaCl, 1 mM 
MESNA, pH 8.0) and left over night at 4°C. The next day M.SssI(Q147L)-thioester was 
eluted with 10 cv of buffer (50 mM NaH2PO4, 300 mM NaCl, 50 mM MESNA, pH 8.0). 
The solution was diluted with 50% v/v of buffer (6.7 mM NaOAc, 6.7 mM MES, 6.7 mM 
Hepes,  1 mM EDTA, 10% glycerol,  2  mM MESNA, pH 7.5) and applied to a  cation 
exchange column (20 ml, Poros HS 50). After washing the column with 5 cv of buffer  
(0.2 M NaCl, 6.7 mM NaOAc, 6.7 mM MES, 6.7 mM Hepes, 1 mM EDTA, 10% glycerol, 
pH 7.5) the protein was eluted with a linear NaCl-gradient (0.2 1 M NaCl) in the total‒  
volume of 10 cv. The protein variants eluted at 700 900 mM NaCl salt concentration. The‒  
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collected  fractions  were  analyzed  by  SDS-PAGE.  The  fractions  containing 
M.SssI(Q147L)-thioester were pooled and concentrated by ultrafiltration (Jumbosep 10K 
and Amicon Centriprep YM-10) to the volume of 550 µl. Aliquots were frozen with liquid 
nitrogen and stored at -80°C. The amount of purified M.SssI(Q147L)-thioester was 1.1 mg.
4.4.3 In vitro activity assay on λ DNA
λ  DNA (50 µg/ml, 3113 5'-CG-3' recognition sites,  4.9 µM) and cofactor AdoMet (1)  
(100 µM) were mixed in reaction buffer (10 mM Tris HCl, 50 mM NaCl, 10 mM DTT, 
pH 7.9). To 38 µl  of  this  solution 2 µl  of  M.SssI,  M.SssI(Q147L) or M.SssI(Q147L)-
thioester (760 ng, 16.7 pmol) were added. Twofold serial delutions (20 µl) were prepared, 
where  the  buffer,  DNA and  cofactor  concentrations  were  constant  and  the  enzyme 
concentration was reduced  by 50% from each  dilution  to  the  next.  The samples  were 
incubated at  30°C for1 h and then at  65°C for  20 min.  Each sample was mixed with 
R.BstUI (10 u) in buffer (30 µl, 10 mM Tris HCl, 50 mM NaCl, 10 mM DTT, 16.7 mM 
MgCl2, pH 7.9) and incubated at 60°C for 1 h. Each sample was treated with proteinase K 
(0.6 mu) and incubated at 37°C for 1 h before analysis by agarose gel electrophoresis (1% 
gel).
For  the  M.SssI(C141S)  variant  and  M.SssI(C141S)-PEG27-HN-C6-TFO  conjugate,  the 
activity assay on λ DNA was performend as follows. λ DNA (50 µg/ml, 3113 5'-CG-3' 
recognition  sites,  4.9  µM),  cofactor  AdoMet  (1)  (100  µM)  were  mixed  with 
M.SssI(C141S)  (5.91,  107.5  pmol),  or  M.SssI(C141S)-PEG27-HN-C6-TFO  (4.86  µg,  
100 pmol) in reaction buffer (25 µl, 10 mM Tris HCl mM NaCl, 10 mM DTT, pH 7.9) and 
incubated at 30°C. After 1, 2, 4, 8 and 24 h samples were taken (5 µl) and incubated at 
65°C for 20 min. Each sample was mixed with R.BstUI (3 u) in buffer (8 µl, 10 mM Tris 
HCl, 50 mM NaCl, 10 mM DTT, 16.7 mM MgCl2, pH 7.9) and incubated at 60°C for 1 h. 
Each sample was treated with proteinase K (0.6 mu) and incubated at 37°C for 1 h before 
analysis by agarose gel electrophoresis (1% gel). 
For  M.SssI•DNA6BAz complex the activity assay on λ DNA was performend as follows.  
λ  DNA (50  µg/ml,  3113  5'-CG-3'  recognition  sites,  4.9  µM),  cofactor  AdoMet  (1,  
100 µM) were mixed with M.SssI•DNA6BAz·(2.3 µg, 38.3 pmol) and M.HhaI (16.3 µg, 440 
pmol)  in  reaction buffer (10 mM Tris HCl,  50 mM NaCl,  10 mM DTT, pH 7.9)  and 
incubated at 37°C. After 1, 2, 4, 6, 8 and 24 h samples were taken and incubated at 65°C 
for 20 min. Each sample was mixed with R.BstUI (3 u) in buffer (8 µl, 10 mM Tris HCl, 
50 mM NaCl, 10 mM DTT, 16.7 mM MgCl2, pH 7.9) and incubated at 60°C for 1 h. Each 
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sample  was  treated with proteinase K (0.6 mu)  and incubated at  37°C for  1  h  before 
analysis by agarose gel electrophoresis (1% gel).
4.5 Bifunctional crosslinker synthesis
4.5.1 Synthesis of Fmoc-NH-PEG27-NHS
O
O
H
N
O
O O
O
N
O
O
27
O
O
H
N
O
O OH
O27
HO N
O
O
Fmoc-NH-PEG27-COOH (10)
Fmoc-NH-PEG27-NHS (12)
The  PEG  linker,  Fmoc-NH-PEG27-COOH  (10)  (3.2  mg,  2.1  µmol)  and  
N-hydroxysuccinimide (292.0 mg, 2500 µmol) was dissolved in dry THF (100 µl) and 
DIC (267.8 mg, 1.3 µmol) dissolved in dry THF (30 µl) was added. THF was dried upon 
molecular  sieves,  4  Å (Acros).  The solution was stirred at  RT for  1  h.  The reaction 
product Fmoc-NH-PEG27-NHS (12) was purified by reversed-phase HPLC (gradient 2, tR 
(Fmoc-NH-PEG27-COOH,  10)  =  15.0  min,  tR (Fmoc-NH-PEG27-NHS)  =  19.0  min). 
Concession  of  product  12  (Fmoc-NH-PEG27-NHS)  was  about  100%  as  analyzed  by 
reversed-phase HPLC. 
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4.6 DNA modifications
4.6.1 Modification with Mal-PEG27-NHS
H2N TFO
TFO
O
H
N
N
O
O
O
O
O27
H
N
H2N-C6-TFO
Mal-PEG27-HN-C6-TFO
7
H2N-C6-TFO (500 µM) was incubated with Mal-PEG27-NHS (7, 20 mM) in buffer (20 µl, 
100 mM NaH2PO4, 150 mM NaCl, 30% DMF, pH 7.4) at RT for 2 h. The reaction product 
(Mal-PEG27-HN-C6-TFO) was purified by  reversed-phase HPLC (gradient 1, tR (H2N-C6-
TFO)  =  12.1  min,  tR (Mal-PEG27-HN-C6-TFO)  =  21.9  min),  lyophilized  to  dryness, 
dissolved in water and desalted by gel filtration (NAP™-5 column). The product yield was 
60%, based on UV absorption (ε260 = 192300 M-1cm-1). 
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4.6.2 Modification with Fmoc-NH-PEG27-NHS and removal of Fmoc group
O
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O27
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N
TFO
H2N TFO
NH3
O
O
O27
H
NH2N
TFO
13
14
Fmoc-NH-PEG27-NHS (12)
H2N-C6-TFO (150 µM) was incubated with Fmoc-NH-PEG27-NHS (12) (1.5 M) in buffer 
(100 µl, 100 mM NaH2PO4, 150 mM NaCl, 50% CH3CN, pH 8.5) at 37°C for 2 h. The 
reaction was analyzed and purified by reversed-phase HPLC (gradient 2, tR (H2N-C6-TFO) 
=  7.2  min,  tR (Fmoc-NH-PEG27-NH-C6-TFO,  13)  =  12.0  min).  Conversion  was 
quantitative. The reaction was lyophilized to dryness and treated with ammonia (100 µl, 
33%) at 37°C for 12 h. Again the sample was lyophilized to dryness, dissolved in water 
and desalted by gel filtration (NAP™-5 column). The product yield (H2N -PEG27-NH-C6-
TFO,  14) was 86% based on UV absorption (ε260 = 192300 M-1cm-1). ESI-Q-TOF m/z = 
8676 (calculated 8676).
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4.6.3 Modification with CMR and removal of Fmoc group
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16
H2N-PEG27-NH-C6-TFO (14) (10 µM) was incubated with CMR (11) (2 mM) in buffer  
(50 µl, 100 mM NaH2PO4, 150 mM NaCl, 50% DMF, pH 8.5) at 37°C for 2 h. The reaction 
was analyzed by reversed-phase HPLC (gradient 2, tR (H2N-PEG27-NH-C6-TFO, 14) = 8.5 
min,  tR (Fmoc-Cys-NH-PEG27-NH-C6-TFO,  15)  =  14.0  min).  The  conversion  was 
quantitative.  The  reaction  was  lyophilized  to  dryness  and  treated  with  ammonia  
(100 µl, 33%) at 37°C for 12 h. Again the sample was lyophilized to dryness, dissolved in 
water and desalted by gel filtration (NAP™-5 column). The product yield (Cys-NH-PEG27-
NH-C6-TFO, 16) was 88% based on UV absorption (ε260 = 192300 M-1cm-1). ESI-Q-TOF, 
m/z = 8867 (calculated 8867).
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4.6.4 Modification with GMBS
H2N
H
N
O
N
O
O
ODN
H2N-C3-ODN Mal-NH-C3-ODN
ODN
O
O
N
O
O
N
O
O 17
 
The H2N-C3-ODN (500 µM) was incubated with GMBS (17) (20 mM) in buffer (20 µl, 
100 mM NaH2PO4, 150 mM NaCl, 30% DMF, pH 7.4) at RT for 2 h. The reaction product 
(Mal-HN-C3-ODN) was purified by reversed-phase HPLC (gradient 1, tR (H2N-C6-ODN) = 
7.3 min, tR (Mal-NH-C3-ODN) = 12.2 min), lyophilized to dryness, dissolved in water and 
desalted by gel filtration (NAP™-5 column). The product yield was 60% based on UV 
absorption (ε260 = 136700 M-1cm-1). 
4.7 Conjugate synthesis
4.7.1 Heterobifunctional crosslinking
A: Coupling M.SssI(C141S) with Mal-PEG27-HN-C6-TFO
M.SssI(C141S) (4.4.1; 400 µg, 20 µM) was incubated with Mal-PEG27-HN-C6-TFO (4.6.1; 
30 µM) in buffer (500 µl, 4.3 mM Na2HPO4, 1.4 mM K2HPO4, 140 mM NaCl, 2.7 mM 
KCl, 0.01% Triton X-100, pH 7.2). After taking samples (1 µl) at 0, 0.25, 0.5, 0.75 and 1 h 
for SDS-PAGE analysis, the remaining reaction volume was centrifuged at 16000 g for  
10 min and the supernatant was mixed with buffer (40 ml, 20 mM Tris HCl, 50 mM NaCl, 
1  mM  EDTA, 10%  glycerin,  0.01%  Triton X-100,  pH  7.6)  and  applied  to  an  anion 
exchange column (DEAE Sepharose Fast Flow, 2.5 ml) at a 1 ml/min flow. The column 
was washed with 10 cv of buffer (40 ml, 20 mM Tris HCl, 50 mM NaCl, 1 mM EDTA, 
10% glycerin, 0.01% Triton X-100, pH 7.6). The product conjugate M.SssI(C141S)-PEG27-
HN-C6-TFO as well as the excess of Mal-PEG27-HN-C6-TFO were eluted from the DEAE 
column in a linear gradient (50 500‒  mM) NaCl in a total volume of 18 cv. The conjugate 
eluted  at  190 270  mM  and  the  Mal-PEG‒ 27-HN-C6-TFO  at  290-350  mM  NaCl, 
respectively. Collected fractions (each 1 ml) were analyzed by SDS-PAGE. The selected 
fractions  with  M.SssI(C141S)-PEG27-HN-C6-TFO  were  pooled  and  concentrated  by 
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ultrafiltration (Amicon Centriprep YM-10 and Microcon YM-10) to the volume of 350 µl, 
mixed 1:1 with glycerol (water-free) and stored at -20°C. The yield of purified conjugate 
was 30% determined by UV absorption (ε280 = 48990 M-1cm-1).
B: Coupling trapped M.SssI with Mal-NH-C3-ODN
M.SssI (200 pmol, 1 µM) was incubated with duplex 13_CG+/- (4.1.3, 400 pmol, 2 µM) 
and 6BAz (9) (2 nmol, 100 µM) in reaction buffer (300 µl, 10 mM Tris HCl, 50 mM NaCl, 
1 mM DTT, pH 7.9) at 37°C for 4 h. Afterwards Mal-NH-C3-ODN (400 pmol; 2 µM) was 
added and samples were taken (20 µl) at 0, 0.25, 0.5 and 1 h for SDS-PAGE analysis. The 
reaction  was  analyzed  on  an  anion  exchange  HPLC  column  (gradient 3,  tR 
(M.SssI•DNA6BAz) = 8.1 min, tR (M.SssI•DNA6BAz-ODN) = 12.0 min, tR (Mal-NH-C3-ODN) 
= 18.1 min, tR (duplex 13_CG+/-) = 19.0 min). The product was purified and concentrated 
by ultrafiltration (Microcon YM-10).
4.7.2 Expressed Protein Ligation
M.SssI(Q147L)-thioester (4.4.2, 15 µM) was incubated with Cys-PEG27-NH-C6-TFO (16, 
150 µM) or  Cys-NH-C3-ODN (from A.  Monami;  150 µM) in  buffer  (10  µl.  100  mM 
NaH2PO4, 100 mM MESNA, 10 mM MgCl2, pH 8.0). Samples were drawn at 0, 4 and  
24 h, mixed with 2  SDS loading buffer and analyzed on SDS-PAGE. 
4.8 Biophysical analysis
4.8.1 In vitro methylation assay on Litcon54 DNA
Circular Litcon54 (4.3.9, 1  µg, 0.55 pmol, 20 nM) was incubated with M.SssI(C141S)-
TFO conjugate (4.7.1,  20,  40,  100 or 200 nM) in reaction buffer (25 µl,  10 mM Tris,
50 mM NaCl, 10 mM MgCl2, pH 7.5) at 30°C. The reaction was terminated after 0, 4 and 
20 h by heat inactivation at 60°C. Afterwards R.Psp1406I (10 u) in reaction buffer (5 µl) 
were added and the solution was incubated at 37°C for 1 h. The reaction products were 
analyzed  by  agarose  gel  electrophoresis  (1%).  In  addition,  the  modified  plasmid  was 
linearized with R.ScaI and analyzed by bisulfite sequencing (4.8.5). 
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4.8.2 DNA thermal denaturation studies
Triple helix thermal denaturation studies were performed by Dipl.-Chem. Matthias Bahr. 
30_TFS+/- duplex DNA (400 pmol, 1 µM) and TFO (400 pmol, 1 µM) in buffer (10 mM 
Tris HCl, 50 mM NaCl, pH 7.5) and different MgCl2 concentrations (0.1 mM to 10 mM) 
were incubated over night at 4ºC. On the next day, UV melting curves were recorded from 
20ºC  to  80ºC  at  a  rate  of  0.5  deg  min-1.  The  absorbance  change  was  monitored  at  
λ = 260 nm.
4.8.3 Kinetic measurements
2-Aminopurine assay
Solutions (600 µl) containing  25_2Ap+/- or 45_2Ap+/- (100 nM) in buffer (10 mM Tris 
HCl,  50  mM  NaCl,  pH  7.5)  and  different  MgCl2 (0.1 10‒  mM)  concentrations  were 
prepared and equilibrated for 5 minutes  at 25°C. Then a solution (100 µl)  of  500 nM 
M.SssI(C141S) or M.SssI(C141S)-TFO in buffer (10 mM Tris HCl, 50 mM NaCl, pH 7.5) 
containing  25_2Ap+/-  or  45_2Ap+/-  (100 nM) was  added  stepwise  and the  change  in 
fluorescence intensity was monitored.  The measured fluorescence intensity curves were 
fitted analytically to model using Excel® Solver.
UV kinetics
Kinetics of triple helix formation were measured based on the hypochromicity change in 
UV absorption at λ = 260 nm. A solution (600 µl) containing duplex 30_TFS+/- (250 nM) 
and 24_TFO (375 nM) in buffer (10 mM Tris HCl, 50 mM NaCl, pH 7.5) was prepared 
and equilibrated  at 25°C for 5 min. Then a solution of MgCl2  (1 M) was added and the 
change in UV absorbance was monitored at λ = 260 nm. The measured absorption curves 
were fitted analytically using Excel® Solver.
4.8.4 FRET 
FRET (fluorescence resonance energy transfer) measurements were performed by Dipl.-
Chem. Matthias Bahr. Fluorophores Alexa 488 and Alexa 555 were used as a FRET pair 
for  the  experiments.  Oligonucleotide  H2N-C6-TFO  was  labeled  with  Alexa  555  and 
30_H2N-C6-TFS+  or  30_H2N-C6-TFS-  were  labeled  with  Alexa  488.  Annealing  of 
complementary  strands  was  done in buffer (10  mM Tris HCl,  50  mM NaCl,  pH 7.5) 
containing different MgCl2 (0.1 10 mM) concentrations.‒
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4.8.5 Bisulfite sequencing
Bisulfite sequencing was performed by Dr. Reinhold Wasserkort from Epigenomics AG in 
Berlin, Germany.
4.8.6 Transfection 
The transfectionn experiments were performed in the group of Dr. Marianne G. Rots in the 
Molecular Biology Department of the UMCG in Groningen, The Netherlands.
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5 APPENDIX
5.1 Abbreviations
2Ap 2-Aminopurine
6BAz
A
N-Adenosylaziridine biotinylated at the N6 position
Adenine or 2'-doexyadenosine 
AdoHcy S-adenosyl-L-homocysteine
AdoMet S-adenosyl-L-methionine
APS Ammonium sodium salt 
ATP Adenosine triphosphate
Az N-Adenosylaziridine 
AzaC 5-Azacytosine
Bp Base pair
BSA Bovine serum albumin
C Cytosine or 2'-doexycytidine
ca. circa
CAM Cell adhesion molecule
CBD Chitin binding domain
C-DNA-MTases DNA cytosine-C5 methyltransferase
CPP Cell penetrating peptide
CT C-terminal
Dam DNA adenine methyltransferase
dC5Me C5-methyl-2'-doexycytidine 
DEAE Diethylaminoethyl
DHAC 5,6-dihydro-5-azacytosine
DMF N,N-Dimethylformamide
DMSO Dimethylsulfoxid
DNA Deoxyribonucleic acid
DNA MTase DNA Methyltransferase
DOPE dioleoylphosphatidylethanolamine
DTT 1,4-Dithio-D,L-threitol
E. coli Escherichia coli
EDTA Ethylendiamintetraacetic acid
EpCAM Epithelial protein cell adhesion molecule
EPL Expressed protein ligation
FdC 5-Fluorodeoxycytidine
Fmoc 9-Fluorenylmethoxycarbonyl
FPLC Fast protein liquid chromatography
G Guanine or 2'-doexyguanosine 
g
GMBS
Gram, or non-SI unit for acceleration
4-Maleimidobutyryloxy-succinimide ester 
h Hours
H3K9 Lysin 9 on histone H3
HEPES N-(2-Hydroxyethyl)piperazin-N'-2-ethansulfonsäure
HPLC High performance liquid chromatography
Hp N-Methyl-3-hydroxypyrrol amino acid
ICF Immunodeficiency, centromer instability 
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Im N-Methylimidazole amino acid
kDa kilo Dalton
λ Wave length
LB Luria-Bertani 
LNA Locked nucleic acid
MALDI Matrix assisted laser desorption ionisation
MESNA 2-Mercapto ethansulfonic acid
min Minute(s)
MO
MS
Morpholinos
Mass spectrum
M.HaeIII DNA cytosine-C5  methyltransferase  from  Haemophilus 
aegypticus
M.HhaI DNA cytosine-C5 methyltransferase  from Haemophilus 
haemolyticus
M.SssI DNA cytosine-C5  methyltransferase  from  Mycoplasma 
sp. strain MQ1
M.TaqI DNA  adenine-N6-methyltransferase  from  Thermus 
aquaticus
MW Molecular weight
Mxe GyrA Intein Gyrase A intein from Mycobacterium xenopi
NCPL Native chemical peptide ligation
N-DNA-MTases DNA adenine-N6, DNA cytosine-N4 methyltransferases
NHS N-hydroxysuccinimidyl
NT N-terminal
OAc Acetate
OD Optical density
ODN Oligodeoxynucleotide
PAGE Polyacrylamide gel electrophoresis
PCR Polymerase chain reaction
pdb Protein data bank
PEG Polyethylene glycol
pI Isoelectric point
PNA Peptide nucleic acid
PTD Protein transduction domain
Py N-Methylpyrrol amino acid
R.BsiEI REase from Bacillus subtilis
R.BstUI REase from Bacillus stearothermophilus
R.NcoI REase from Nocardia corallina
R.PstI REase from Providencia stuartii
R.SacI REase from Streptomyces achromogenes
R.ScaI REase from Streptomyces caespitosus
R.XbaI REase from Xanthomonas badrii
REase Restriction endonuclease
RNA Ribonucleic acid
Rpm Rounds per minute
RT Room temperature
SAINT Synthetic amphiphile interaction
SAINT-2 N-Methyl-4-(dioleolyl)methyl-pyridiniumchloride
SD SAINT-2:DOPE
SDS Sodium dodecylsulfate
siRNA Small interfering RNA
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T Thymine or 2'-deoxythymidine
tR Retention time
TBE
TEAAc
Tris/Borate/EDTA
Triethylammonium acetate
TEMED N,N,N',N'-tetramethylethylendiamine
TFO Triple helix-forming oligodeoxynucleotide
TFS Triple helix-forming site
Tris 2-Amino-2-(hydroxymethyl)-1,3-propandiol
u Enzymatic unit
V Voltage
Zeb Zebularine
5.2 Three and one letter amino acid codes
Ala A Alanine
Arg R Arginine
Asn N Asparagine
Asp D Aspartic acid
Cys C Cysteine
Glu E Glutamic acid
Gln Q Glutamine
Gly G Glycine
His H Histidine
Ile I Isoleucine
Leu L Leucine
Lys K Lysine
Met M Methionine
Phe F Phenylalanine
Pro P Proline
Ser S Serine
Thr T Threonine
Try W Tryptophan
Tyr Y Tyrosine
Val V Valine
Protein sequences are given starting from N- to C-terminal.  Mutations are indicated in 
brackets next to the protein name (mutated amino acid; position; inserted amino acid).
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5.3 Sequences of M.SssI variants
M.SssI(C141S) 
MW = 45295.6 g/mol
pI = 9.19
MSKVENKTKK LRVFEAFAGI GAQRKALEKV RKDEYEIVGL AEWYVPAIVM YQAIHNNFHT 
KLEYKSVSRE EMIDYLENKT LSWNSKNPVS NGYWKRKKDD ELKIIYNAIK LSEKEGNIFD 
IRDLYKRTLK NIDLLTYSFP SQDLSQQGIQ KGMKRGSGTR SGLLWEIERA LDSTEKNDLP 
KYLLMENVGA LLHKKNEEEL NQWKQKLESL GYQNSIEVLN AADFGSSQAR RRVFMISTLN 
EFVELPKGDK KPKSIKKVLN KIVSEKDILN NLLKYNLTEF KKTKSNINKA SLIGYSKFNS 
EGYVYDPEFT GPTLTASGAN SRIKIKDGSN IRKMNSDETF LYMGFDSQDG KRVNEIEFLT 
ENQKIFVAGN SISVEVLEAI IDKIGGSHHHHHHC
M.SssI 
MW = 45327,8 g/mol 
pI = 9.12
MCKVENKTKK LRVFEAFAGI GAQRKALEKV RKDEYEIVGL AEWYVPAIVM YQAIHNNFHT 
KLEYKSVSRE EMIDYLENKT LSWNSKNPVS NGYWKRKKDD ELKIIYNAIK LSEKEGNIFD 
IRDLYKRTLK NIDLLTYSFP CQDLSQQGIQ KGMKRGSGTR SGLLWEIERA LDSTEKNDLP 
KYLLMENVGA LLHKKNEEEL NQWKQKLESL GYQNSIEVLN AADFGSSQAR RRVFMISTLN 
EFVELPKGDK KPKSIKKVLN KIVSEKDILN NLLKYNLTEF KKTKSNINKA SLIGYSKFNS
EGYVYDPEFT GPTLTASGAN SRIKIKDGSN IRKMNSDETF LYMGFDSQDG KRVNEIEFLT 
ENQKIFVAGN SISVEVLEAI IDKIGGSHHH HHHC
M.SssI(Q147L)
MW = 45296.7 g/mol
pI = 9.15
MSKVENKTKK LRVFEAFAGI GAQRKALEKV RKDEYEIVGL AEWYVPAIVM YQAIHNNFHT 
KLEYKSVSRE EMIDYLENKT LSWNSKNPVS NGYWKRKKDD ELKIIYNAIK LSEKEGNIFD 
IRDLYKRTLK NIDLLTYSFP CQDLSQLGIQ KGMKRGSGTR SGLLWEIERA LDSTEKNDLP 
KYLLMENVGA LLHKKNEEEL NQWKQKLESL GYQNSIEVLN AADFGSSQAR RRVFMISTLN 
EFVELPKGDK KPKSIKKVLN KIVSEKDILN NLLKYNLTEF KKTKSNINKA SLIGYSKFNS 
EGYVYDPEFT GPTLTASGAN SRIKIKDGSN IRKMNSDETF LYMGFDSQDG KRVNEIEFLT 
ENQKIFVAGN SISVEVLEAI IDKIGGSHHHHHHC
91
APPENDIX
M.SssI(Q147L)-Y-Mxe GyrA-CBD-His6
MW = 73487.5 g/mol
pI = 8.22
MCKVENKTKK LRVFEAFAGI GAQRKALEKV RKDEYEIVGL AEWYVPAIVM YQAIHNNFHT 
KLEYKSVSRE EMIDYLENKT LSWNSKNPVS NGYWKRKKDD ELKIIYNAIK LSEKEGNIFD 
IRDLYKRTLK NIDLLTYSFP CQDLSQLGIQ KGMKRGSGTR SGLLWEIERA LDSTEKNDLP 
KYLLMENVGA LLHKKNEEEL NQWKQKLESL GYQNSIEVLN AADFGSSQAR RRVFMISTLN 
EFVELPKGDK KPKSIKKVLN KIVSEKDILN NLLKYNLTEF KKTKSNINKA SLIGYSKFNS 
EGYVYDPEFT GPTLTASGAN SRIKIKDGSN IRKMNSDETF LYMGFDSQDG KRVNEIEFLT 
ENQKIFVAGN SISVEVLEAI IDKIGGAMGS YCITGDALVA LPEGESVRIA DIVPGARPNS 
DNAIDLKVLD RHGNPVLADR LFHSGEHPVY TVRTVEGLRV TGTANHPLLC LVDVAGVPTL 
LWKLIDEIKP GDYAVIQRSA FSVDCAGFAR GKPEFAPTTY TVGVPGLVRF LEAHHRDPDA 
QAIADELTDG RFYYAKVASV TDAGVQPVYS LRVDTADHAF ITNGFVSHAT GLTGLNSGLT 
TNPGVSAWQV NTAYTAGQLV TYNGKTYKCL QPHTSLAGWE PSNVPALWQL QHHHHHH
The His6 affinity tag and  the  Mxe GyrA intein  fragment  are  highlighted in  gray. The 
physical properties were calculated by ProtPram available on www.expasy.com.
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